17 NULL NULL NULL NULL mediated gene transfer of endostatin 
17 of endostatin in vivo results in high level of 
9 high level of transgene expression and inhibition of tumor 
18 of transgene expression and inhibition of tumor growth and 
0 expression and inhibition of tumor growth and metastases . 
4 and inhibition of tumor growth and metastases . NULL 
14 of tumor growth and metastases . NULL NULL NULL 
18 NULL NULL NULL NULL inhibition of angiogenesis has been 
3 NULL NULL inhibition of angiogenesis has been shown to 
0 shown to be an effective strategy in cancer therapy 
19 effective strategy in cancer therapy in mice . NULL 
0 however , its widespread application has been hampered by 
0 difficulties in the large-scale production of the antiangiogenic proteins 
3 large-scale production of the angiogenic proteins . NULL NULL 
0 resolved by in vivo delivery and expression of the 
0 in vivo delivery and expression of the antiangiogenic genes 
3 and expression of the angiogenic genes . NULL NULL 
19 NULL NULL we have constructed a recombinant adenovirus that 
0 endostatin that is biologically active both in vitro , 
1 determined in endothelial cell proliferation assays , and in 
18 in vivo , by suppression of angiogenesis induced by 
3 , by suppression of angiogenesis induced by vascular endothelial 
17 by suppression of angiogenesis induced by vascular endothelial growth 
0 induced by vascular endothelial growth factor 165 . NULL 
0 NULL persistent high serum levels of endostatin ( 605-1740 
19 were achieved after systemic administration of the vector to 
17 nude mice , which resulted in significant reduction of 
0 , which resulted in significant reduction of the growth 
18 which resulted in significant reduction of the growth rates 
4 significant reduction of the growth rates and the volumes 
0 NULL NULL NULL in addition , the endostatin vector 
19 , the endostatin vector treatment completely prevented the formation 
18 endostatin vector treatment completely prevented the formation of pulmonary 
2 treatment completely prevented the formation of pulmonary micrometastases in 
0 NULL NULL NULL NULL immunohistochemical staining of the tumors 
0 NULL NULL NULL immunohistochemical staining of the tumors demonstrated 
18 the tumors demonstrated a decreased number of blood vessels 
0 blood vessels in the treatment group versus the controls 
0 treatment group versus the controls . NULL NULL NULL 
0 in conclusion , the present study clearly demonstrates the 
0 study clearly demonstrates the potential of vector-mediated antiangiogenic gene 
0 demonstrates the potential of mediated antiangiogenic gene therapy as 
3 the potential of vector-mediated angiogenic gene therapy as a 
0 of vector-mediated antiangiogenic gene therapy as a component in 
19 a component in cancer therapy . NULL NULL NULL 
14 endothelial cells , which migrate to and occupy positions 
2 these cells coalesce and form cords , which lumenize 
0 and become ensheathed by supporting pericytes and smooth muscle 
0 , and expanded by sprouting in others . NULL 
0 uncovered a number of signals that guide these complex 
0 that guide these complex processes but many gaps still 
0 because many questions will require in vivo studies to 
0 in identifying new molecules involved in blood vessel development 
2 involved in blood vessel development and integrating pathways that 
0 vessel development and integrating pathways that influence embryonic blood 
0 and integrating pathways that influence embryonic blood vessel formation 
2 influence embryonic blood vessel formation . NULL NULL NULL 
0 NULL a small peptide derived from flt-1 ( vegfr-1 
0 flt-1 ( vegfr-1 ) functions as an angiogenic inhibitor 
3 ) functions as an angiogenic inhibitor . NULL NULL 
18 functions as an angiogenic inhibitor . NULL NULL NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
3 vegf ) is an angiogenic stimulator which functions through 
16 an angiogenic stimulator which functions through two endothelial specific 
0 an 11-amino acid peptide derived from the second immunoglobulin-like 
0 immunoglobulin-like domain of flt-1 functions as an angiogenic inhibitor 
3 flt-1 functions as an angiogenic inhibitor in chick chorioallantoic 
18 functions as an angiogenic inhibitor in chick chorioallantoic membrane 
0 chick chorioallantoic membrane and inhibited vegf-induced vascular permeability in 
0 chorioallantoic membrane and inhibited induced vascular permeability in miles 
15 miles ' assay without binding to vegf directly . 
0 peptide forms a stable extended structure in solution , 
0 NULL NULL NULL our results suggest that this small 
0 that this small peptide functions as an angiogenic inhibitor 
3 peptide functions as an angiogenic inhibitor by inhibiting vegf 
0 functions as an angiogenic inhibitor by inhibiting vegf function 
18 an angiogenic inhibitor by inhibiting vegf function through a 
0 inhibitor by inhibiting vegf function through a non-vegf binding 
15 function through a non-vegf binding mechanism . NULL NULL 
0 through a non-vegf binding mechanism . NULL NULL NULL 
9 NULL NULL NULL NULL coexpression of vascular endothelial growth 
0 coexpression of vascular endothelial growth factor and p53 protein 
0 growth factor and p53 protein in squamous cell carcinoma 
16 NULL objective : p53 plays a role in tumor 
16 : p53 plays a role in tumor angiogenesis , 
0 plays a role in tumor angiogenesis , and vascular 
3 a role in tumor angiogenesis , and vascular endothelial 
0 , and vascular endothelial growth factor ( vegf ) 
16 factor ( vegf ) plays a key role in 
16 vegf ) plays a key role in tumor angiogenesis 
16 ) plays a key role in tumor angiogenesis . 
0 a key role in tumor angiogenesis . NULL NULL 
3 key role in tumor angiogenesis . NULL NULL NULL 
0 the aim of the present study was to clarify 
9 was to clarify how expression of p53 protein participates 
0 how expression of p53 protein participates in angiogenesis , 
3 p53 protein participates in angiogenesis , and whether the 
9 , and whether the coexpression of vegf and p53 
0 of vegf and p53 protein has a significance for 
3 has a significance for angiogenesis and the clinicopathological features 
19 with esophageal scc after surgery . NULL NULL NULL 
9 NULL NULL NULL the expression of vegf and p53 
0 of vegf and p53 protein in these scc was 
0 by counting microvessels in tumor sections stained for factor 
0 immunostaining , as a proliferative marker . NULL NULL 
0 on the terminal deoxynucleotidyl mediated deoxyuridine triphosphate biotin nick 
0 labeling , to evaluate apoptosis . NULL NULL NULL 
0 NULL NULL NULL NULL results : vegf expression was 
9 NULL results : vegf expression was observed in 58.3 
0 : vegf expression was observed in 58.3 % , 
0 % , and p53 protein expression was observed in 
9 , and p53 protein expression was observed in 61.7 
0 p53 protein expression was observed in 61.7 % of 
0 NULL vegf and p53 protein were significantly coexpressed in 
9 p53 protein were significantly coexpressed in 26 ( 43.4 
14 NULL NULL histological venous invasion ( p less than 
0 0.01 ) and distant metastasis ( p less than 
0 significantly correlated with p53 protein expression . NULL NULL 
9 correlated with p53 protein expression . NULL NULL NULL 
0 parameters were more frequently observed in the scc with 
9 the scc with vegf/p53 coexpression than in those without 
9 in those without the coexpression . NULL NULL NULL 
0 the scc with p53 protein expression than in the 
9 scc with p53 protein expression than in the scc 
9 the scc with vegf/p53 coexpression than in those without 
9 in those without the coexpression . NULL NULL NULL 
0 NULL NULL the 5-yr survival rate in patients with 
9 in patients with the coexpression was poorer than in 
0 NULL conclusion : these results suggest that mutant p53 
9 suggest that mutant p53 expression is associated with angiogenesis 
0 mutant p53 expression is associated with angiogenesis and distant 
3 expression is associated with angiogenesis and distant metastasis in 
0 with angiogenesis and distant metastasis in esophageal scc , 
9 , and that the coexpression of p53 and vegf 
16 p53 and vegf may play an important role in 
16 vegf may play an important role in angiogenesis , 
16 may play an important role in angiogenesis , and 
3 an important role in angiogenesis , and have important 
0 angiogenesis , and have important clinical significance . NULL 
0 , and have important clinical significance . NULL NULL 
18 NULL NULL troponin i inhibits capillary endothelial cell proliferation 
1 inhibits capillary endothelial cell proliferation by interaction with the 
15 endothelial cell proliferation by interaction with the cell 's 
0 ) is a novel derived angiogenesis inhibitor , first 
3 is a novel cartilage-derived angiogenesis inhibitor , first demonstrated 
0 a novel cartilage-derived angiogenesis inhibitor , first demonstrated by 
18 usa 2645-2650 ) to inhibit endothelial cell proliferation and 
1 to inhibit endothelial cell proliferation and angiogenesis , both 
3 endothelial cell proliferation and angiogenesis , both in vivo 
18 vitro , and to inhibit metastasis of a wide 
14 , and to inhibit metastasis of a wide variety 
0 convincing evidence of its efficacy , little is known 
0 is known about the mechanism of action of tni 
0 about the mechanism of action of tni as an 
0 of tni as an proliferative and anti-angiogenic agent . 
3 as an anti-proliferative and angiogenic agent . NULL NULL 
18 we demonstrate that tni inhibits both bfgf-stimulated and basal 
17 that tni inhibits both stimulated and basal levels of 
0 both bfgf-stimulated and basal levels of endothelial cell proliferation 
1 levels of endothelial cell proliferation , and we hypothesize 
18 we hypothesize that this inhibition is occurring , at 
15 part , via an interaction of tni with the 
0 NULL NULL we further support this hypothesis by providing 
16 evidence that tni can act on nonendothelial as well 
18 by demonstrating that this inhibitory action is specific for 
18 demonstrating that this inhibitory action is specific for the 
0 bfgf receptor on the target cells . NULL NULL 
15 competing with bfgf for interaction with the bfgf receptor 
0 NULL NULL NULL NULL clinical significance of plasma endostatin 
3 , is an endogenous angiogenesis inhibitor . NULL NULL 
0 is an endogenous angiogenesis inhibitor . NULL NULL NULL 
19 for its usefulness in treating solid tumors , its 
0 endostatin ( pe ) levels using an enzyme linked 
19 levels using an enzyme linked immunoassay in 71 patients 
0 correlated pe with various clinical parameters . NULL NULL 
0 NULL NULL NULL NULL results : there was no 
0 : there was no significant difference in the median 
0 patients and the normal controls . NULL NULL NULL 
0 found to be a significant ( p = 0.03 
0 ) predictor of overall survival ( os ) with 
0 disorders , and the use of protective environments . 
0 pe level of normal controls as the cut-off . 
5 the high pe group survived for a significantly shorter 
0 NULL NULL NULL the mechanism underlying the association between 
0 the mechanism underlying the association between high pe and 
0 high pe and poor clinical outcome is unclear , 
0 possible pe reflection of tumor burden . NULL NULL 
16 NULL NULL NULL NULL modulation of angiogenesis and progelatinase 
3 NULL NULL modulation of angiogenesis and progelatinase a by 
3 NULL NULL NULL the angiogenic action of thrombin has 
0 NULL NULL the angiogenic action of thrombin has been 
16 been shown to be mediated by activation of the 
17 to be mediated by activation of the thrombin receptor 
16 report we studied the effects of sfllr , an 
17 an agonist of the activated thrombin receptor and thrombin 
3 non peptide antagonists on angiogenesis in the chick chorioallantoic 
0 NULL as antagonists were used the tripeptide fpr and 
0 , like thrombin , caused a marked stimulation of 
17 , caused a marked stimulation of angiogenesis in the 
3 a marked stimulation of angiogenesis in the cam . 
0 and the piperazine derivatives caused suppression of angiogenesis and 
18 the piperazine derivatives caused suppression of angiogenesis and in 
3 derivatives caused suppression of angiogenesis and in combination with 
3 with thrombin antagonized its angiogenic effect . NULL NULL 
0 thrombin antagonized its angiogenic effect . NULL NULL NULL 
17 NULL thrombin and sfllr activated progelatinase a ( mmp-2 
0 mmp-2 ) in the culture medium of human umbilical 
0 NULL NULL mmp-2 is involved in the early steps 
3 the early steps of angiogenesis leading to local dissolution 
17 early steps of angiogenesis leading to local dissolution of 
11 angiogenesis leading to local dissolution of basement membrane collagen 
14 basement membrane collagen and migration of the activated endothelial 
17 and migration of the activated endothelial cells . NULL 
18 and the piperazine derivatives inhibited the activation of this 
17 piperazine derivatives inhibited the activation of this enzyme . 
16 they also antagonised the effects of both thrombin and 
17 and sfllr on mmp-2 activation . NULL NULL NULL 
0 NULL NULL NULL these results suggest that non-thrombogenic agonists 
17 or antagonists of the activated thrombin receptor can be 
0 thrombin receptor can be used as modulators of angiogenesis 
3 used as modulators of angiogenesis . NULL NULL NULL 
16 NULL NULL NULL vegf165 mediates formation of complexes containing 
15 NULL NULL vegf165 mediates formation of complexes containing vegfr-2 
17 vegfr-2 and neuropilin-1 that enhance vegf165-receptor binding . NULL 
15 neuropilin-1 that enhance vegf165-receptor binding . NULL NULL NULL 
9 NULL NULL NULL NULL expression of nrp1 and ( 
17 cells ( ec ) enhances vegf165 binding to kdr 
15 ec ) enhances vegf165 binding to kdr and ec 
14 to kdr and ec chemotaxis in response to vegf165 
17 and ec chemotaxis in response to vegf165 . NULL 
9 NULL NULL NULL NULL overexpression of nrp1 by prostate 
0 of nrp1 by prostate tumor cells in vivo results 
0 tumor cells in vivo results in increased tumor angiogenesis 
17 in vivo results in increased tumor angiogenesis and growth 
0 vivo results in increased tumor angiogenesis and growth . 
3 results in increased tumor angiogenesis and growth . NULL 
4 increased tumor angiogenesis and growth . NULL NULL NULL 
17 the molecular mechanisms underlying mediated angiogenesis by analyzing the 
3 molecular mechanisms underlying nrp1-mediated angiogenesis by analyzing the association 
15 angiogenesis by analyzing the association of nrp1 and kdr 
0 antibodies only in the presence of vegf165 . NULL 
15 , which does not bind to nrp1 , did 
17 nrp1 , did not support complex formation . NULL 
15 did not support complex formation . NULL NULL NULL 
15 and kdr were also formed in an intercellular fashion 
19 an intercellular fashion by culture of ec expressing kdr 
9 by co-culture of ec expressing kdr only , with 
9 only , with cells expressing nrp1 only , for 
16 NULL NULL vegf165 also mediated the binding of a 
15 vegf165 also mediated the binding of a soluble nrp1 
9 nrp1 dimer to cells expressing kdr only , confirming 
0 only , confirming the formation of such complexes . 
15 NULL furthermore , the formation of complexes containing kdr 
17 kdr and nrp1 markedly increased 125i-vegf165 binding to kdr 
15 nrp1 markedly increased 125i-vegf165 binding to kdr . NULL 
0 NULL NULL NULL our results suggest that formation of 
15 our results suggest that formation of a ternary complex 
17 kdr , and nrp1 potentiates vegf165 binding to kdr 
15 and nrp1 potentiates vegf165 binding to kdr . NULL 
15 NULL these complexes are formed on the surface of 
15 a juxtacrine manner via association of tumor cell nrp1 
0 manner via association of tumor cell nrp1 and ec 
17 NULL NULL NULL hypoxic induction of hif-1alpha and vegf 
9 of hif-1alpha and vegf expression in head and neck 
16 cell carcinoma lines is mediated by stress activated protein 
0 is mediated by stress activated protein kinases . NULL 
0 mediated by stress activated protein kinases . NULL NULL 
4 supply in order to proliferate and grow . NULL 
4 order to proliferate and grow . NULL NULL NULL 
17 soluble factors which can induce proliferation and migration of 
1 factors which can induce proliferation and migration of capillary 
14 can induce proliferation and migration of capillary endothelial cells 
3 most potent of the angiogenic factors is vascular endothelial 
0 factors is vascular endothelial growth factor ( vegf ) 
17 NULL NULL NULL NULL increased vegf expression by malignant 
9 NULL NULL increased vegf expression by malignant tumors has 
0 increased vegf expression by malignant tumors has been associated 
16 malignant tumors has been associated with high vascularity , 
17 with high vascularity , increased cancer cell growth , 
1 , increased cancer cell growth , and lymph node 
14 , and lymph node metastasis . NULL NULL NULL 
18 NULL NULL NULL NULL reduced oxygen tension has been 
17 has been shown to increase vegf production by induction 
9 shown to increase vegf production by induction of the 
17 increase vegf production by induction of the transcription factor 
0 by induction of the transcription factor hypoxia inducible factor 
0 the transcription factor hypoxia inducible factor 1 alpha ( 
0 mechanisms by which hypoxic tumor environments induce hif-1alpha and 
17 which hypoxic tumor environments induce hif-1alpha and vegf expression 
9 induce hif-1alpha and vegf expression are largely unknown . 
17 and p38 kinase are activated by a variety of 
0 to determine if hypoxic activation of these stress activated 
0 activation of these stress activated protein kinases regulated hif-1alpha 
0 of these stress activated protein kinases regulated hif-1alpha and 
16 stress activated protein kinases regulated hif-1alpha and vegf expression 
9 regulated hif-1alpha and vegf expression , we assayed jnk1 
0 vegf expression , we assayed jnk1 and p38 activity 
0 assayed jnk1 and p38 activity in squamous cell carcinoma 
0 ( scc ) lines grown under normoxic or hypoxic 
17 NULL NULL hypoxia rapidly induced both jnk1 and p38 
0 both jnk1 and p38 activity in these cells . 
17 NULL NULL NULL this activation correlated with induction of 
17 this activation correlated with induction of hif-1alpha expression and 
9 with induction of hif-1alpha expression and dna binding activity 
15 hif-1alpha expression and dna binding activity which was blocked 
0 expression and dna binding activity which was blocked by 
18 binding activity which was blocked by the p38 inhibitor 
0 blocked by the p38 inhibitor sb203580 . NULL NULL 
17 NULL NULL hypoxia also increased vegf production by scc 
9 hypoxia also increased vegf production by scc lines , 
0 lines , which was inhibited by treatment with sb203580 
19 which was inhibited by treatment with sb203580 . NULL 
9 NULL NULL NULL NULL overexpression of jnk1 or p38 
0 jnk1 or p38 was sufficient to induce hif-1alpha and 
17 p38 was sufficient to induce hif-1alpha and vegf expression 
9 induce hif-1alpha and vegf expression . NULL NULL NULL 
0 NULL NULL NULL these results indicate that induction of 
17 these results indicate that induction of sapks by hypoxia 
16 of sapks by hypoxia regulates hif-1alpha and vegf expression 
9 regulates hif-1alpha and vegf expression in head and neck 
0 patterns of benign and malignant breast lesions ( masses 
0 the stromal fibrous reaction associated to infiltrating carcinomas is 
14 fibrous reaction associated to infiltrating carcinomas is responsible of 
0 to infiltrating carcinomas is responsible of focal increased density 
0 is responsible of focal increased density , and architectural 
3 acoustic shadowing ; abnormal angiogenesis can be detected by 
0 abnormal neoangiogenesis can be detected by doppler , ct 
2 spiculated margins are poorly differentiated tumors . NULL NULL 
0 their physiopathological process ( necrosis , secretion ) , 
0 process ( necrosis , secretion ) , and the 
0 ) , and the shape of clusters ( round 
0 was identified as a tumor suppressor gene on the 
18 identified as a tumor suppressor gene on the long 
0 NULL since then , important progress has been made 
16 the understanding of the role of the pten protein 
0 role of the pten protein in the normal development 
2 protein in the normal development of the brain as 
0 as in the molecular pathogenesis of human gliomas . 
0 the art concerning the involvement of aberrant pten function 
16 concerning the involvement of aberrant pten function in the 
0 involvement of aberrant pten function in the development of 
2 pten function in the development of different biologic features 
0 different biologic features of malignant gliomas , such as 
0 gliomas , such as loss of cell-cycle control and 
0 as loss of cell-cycle control and uncontrolled cell proliferation 
1 control and uncontrolled cell proliferation , escape from apoptosis 
5 proliferation , escape from apoptosis , brain invasion , 
14 from apoptosis , brain invasion , and aberrant neoangiogenesis 
16 brain invasion , and aberrant neoangiogenesis . NULL NULL 
3 invasion , and aberrant angiogenesis . NULL NULL NULL 
0 NULL most of the tumor-suppressive properties of pten are 
0 most of the tumor-suppressive properties of pten are dependent 
16 properties of pten are dependent on its lipid phosphatase 
0 on its lipid phosphatase activity , which inhibits the 
18 phosphatase activity , which inhibits the phosphatidylinositol-3'-kinase ( pi3k 
16 phosphatase activity , which inhibits the phosphatidylinositol-3'-kinase ( pi3k 
13 /akt signaling pathway through dephosphorylation of phosphatidylinositol- ( 3 
0 NULL NULL the additional function of pten as a 
0 pten as a dual-specificity protein phosphatase may also play 
16 protein phosphatase may also play a role in glioma 
16 may also play a role in glioma pathogenesis . 
0 a role in glioma pathogenesis . NULL NULL NULL 
0 data elucidating the functional roles of pten , recent 
16 significance of pten gene alterations as a molecular marker 
19 the possibility of selective targeting of pten mutant tumor 
0 targeting of pten mutant tumor cells by specific pharmacologic 
0 new perspectives for a targeted molecular therapy of malignant 
19 for a targeted molecular therapy of malignant gliomas . 
0 targeted molecular therapy of malignant gliomas . NULL NULL 
0 NULL NULL NULL systemic regulation of distraction osteogenesis : 
0 NULL systemic regulation of distraction osteogenesis : a cascade 
0 systemic regulation of distraction osteogenesis : a cascade of 
0 investigates the systemic biochemical regulation of fracture healing in 
0 of fracture healing in distraction osteogenesis compared with rigid 
0 fracture healing in distraction osteogenesis compared with rigid osteotomy 
0 to further clarify the influence of mechanical strain on 
16 mechanical strain on the regulation of bone formation , 
2 the regulation of bone formation , bone growth factors 
0 bone formation , bone growth factors ( insulin-like growth 
0 growth factors ( insulin-like growth factor [ igf ] 
0 ] i , igf binding protein [ igfbp ] 
0 i , igf binding protein [ igfbp ] 3 
0 ] 3 , transforming growth factor [ tgf ] 
0 ] ) , bone matrix degrading enzymes ( matrix-metalloproteinases 
0 matrix degrading enzymes ( matrix [ mmps ] 1 
0 3 ) , human growth hormone ( hgh ) 
0 ) , and bone formation markers ( alp , 
0 NULL NULL in the distraction group , a significant 
0 distraction group , a significant postoperative increase in mmp-1 
17 , a significant postoperative increase in mmp-1 , bfgf 
0 and bap could be observed during the lengthening and 
0 compared with the baseline levels . NULL NULL NULL 
0 traction stimulus failed to induce a corresponding increase in 
0 to induce a corresponding increase in these factors . 
0 NULL NULL NULL in addition , comparison of both 
17 revealed a significantly higher increase in tgf-beta1 , igf-i 
0 lengthening group during the distraction period , indicating key 
0 distraction period , indicating key regulatory functions in mechanotransduction 
0 period , indicating key regulatory functions in mechanotransduction . 
0 , indicating key regulatory functions in mechanotransduction . NULL 
16 the time courses of changes in mmp-1 , bone 
0 in mmp-1 , bone growth factors ( tgf-beta1 and 
0 phase , indicating common regulatory pathways for these factors 
0 , indicating common regulatory pathways for these factors in 
0 for these factors in distraction osteogenesis . NULL NULL 
0 these factors in distraction osteogenesis . NULL NULL NULL 
0 NULL NULL NULL NULL significant correlation between the osteoblastic 
17 , and bfgf suggests activated osteoblastic cells as a 
0 osteoblastic cells as a major source of systemically increased 
0 major source of systemically increased bone growth factors during 
0 of systemically increased bone growth factors during callus distraction 
0 growth factors during callus distraction . NULL NULL NULL 
17 NULL NULL the systemic increase in bfgf and mmp-1 
0 bfgf and mmp-1 might reflect an increased local stimulation 
17 mmp-1 might reflect an increased local stimulation of angiogenesis 
17 reflect an increased local stimulation of angiogenesis during distraction 
3 increased local stimulation of angiogenesis during distraction osteogenesis . 
0 stimulation of angiogenesis during distraction osteogenesis . NULL NULL 
0 of angiogenesis during distraction osteogenesis . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenic and antitumor effects of 
18 NULL antiangiogenic and antitumor effects of a protein kinase 
0 antitumor effects of a protein kinase cbeta inhibitor in 
0 a protein kinase cbeta inhibitor in human breast cancer 
19 NULL NULL in cell culture , the compound 317615 
18 2hcl , a potent inhibitor of vegf-stimulated huvec proliferation 
17 a potent inhibitor of stimulated huvec proliferation , was 
1 inhibitor of vegf-stimulated huvec proliferation , was not very 
18 , was not very effective against mx-1 breast cancer 
19 NULL NULL NULL NULL exposure to combinations of paclitaxel 
0 with mx-1 cells in culture resulted in cell survival 
17 mx-1 cells in culture resulted in cell survival that 
5 culture resulted in cell survival that reflected primarily additivity 
19 NULL NULL NULL NULL exposure of skov-3 cells to 
17 along with 317615 2hcl resulted in cell survivals that 
19 NULL NULL NULL NULL administration of 317615 x 2hci 
17 tumors or skov-3 tumors resulted in a decreased number 
18 tumors resulted in a decreased number of intratumoral vessels 
0 by cd31 and cd105 staining with decreases of 35 
0 and cd105 staining with decreases of 35 % and 
0 x 2hcl was an active antitumor agent against the 
17 the mx-1 xenograft and increased the tumor growth delay 
0 xenograft and increased the tumor growth delay produced by 
4 and increased the tumor growth delay produced by paclitaxel 
18 increased the tumor growth delay produced by paclitaxel by 
0 the tumor growth delay produced by paclitaxel by 1.7-fold 
0 by 1.7-fold and the tumor growth delay produced by 
4 1.7-fold and the tumor growth delay produced by carboplatin 
18 and the tumor growth delay produced by carboplatin by 
0 the tumor growth delay produced by carboplatin by 3.8-fold 
19 NULL NULL NULL NULL administration of 317615 x 2hcl 
17 317615 x 2hcl also increased the tumor growth delay 
0 2hcl also increased the tumor growth delay produced by 
4 also increased the tumor growth delay produced by fractionated 
18 increased the tumor growth delay produced by fractionated radiation 
0 the tumor growth delay produced by fractionated radiation therapy 
0 delay produced by fractionated radiation therapy in the mx-1 
0 produced by fractionated radiation therapy in the mx-1 tumor 
0 therapy in the mx-1 tumor . NULL NULL NULL 
19 NULL NULL NULL NULL treatment with 317615 x 2hcl 
0 317615 x 2hcl alone increased the lifespan of animals 
0 1.9 fold compared with untreated control animals . NULL 
0 fold compared with untreated control animals . NULL NULL 
0 and 317615 x 2hcl resulted in 100 % 120-day 
0 in 100 % 120-day survival of skov-3 bearing animals 
19 NULL NULL NULL NULL administration of 317615 x 2hcl 
0 animals bearing the skov-3 tumor produced a 1.8-fold increase 
0 bearing the skov-3 tumor produced a 1.8-fold increase in 
0 tumor produced a 1.8-fold increase in lifespan compared with 
3 is a promising new angiogenic agent that is in 
0 is in early phase clinical testing . NULL NULL 
0 NULL NULL NULL fibroblast growth factor 2 promotes microvessel 
17 fibroblast growth factor 2 promotes microvessel formation from mouse 
2 factor 2 promotes microvessel formation from mouse embryonic aorta 
0 NULL to delineate the roles that oxygen and fibroblast 
0 that oxygen and fibroblast growth factors ( fgfs ) 
16 factors ( fgfs ) play in the process of 
3 in the process of angiogenesis from the embryonic aorta 
19 embryonic aorta , we cultured mouse embryonic aorta explants 
0 type i collagen gel matrix . NULL NULL NULL 
0 during 8 days of culture under 5 % o 
19 room air , the addition of fgf2 to explants 
17 of fgf2 to explants stimulated the formation of gs-ib 
2 to explants stimulated the formation of gs-ib ( 4- 
0 gs-ib ( 4- ) positive , cd31-positive , and 
0 4- ) positive , positive , and flk-1-positive microvessels 
0 , cd31-positive , and positive microvessels in a concentration-dependent 
0 flk-1-positive microvessels in a dependent manner . NULL NULL 
17 NULL NULL NULL NULL stimulated microvessel formation was inhibited 
2 NULL NULL fgf2-stimulated microvessel formation was inhibited by sequestration 
18 fgf2-stimulated microvessel formation was inhibited by sequestration of fgf2 
19 sequestration of fgf2 via addition of soluble fgf receptor 
0 ( fgfr ) chimera protein or anti-fgf2 antibodies . 
0 fgfr1 and fgfr2 were present on explants . NULL 
0 NULL NULL NULL NULL levels of fgfr1 , but 
17 not fgfr2 , were increased in embryonic aorta cultured 
19 increased in embryonic aorta cultured under 5 % o 
9 low oxygen upregulates fgfr1 expression in embryonic aorta in 
0 NULL NULL NULL insulin-like growth factor-i receptor-mediated vasculogenesis/angiogenesis in 
16 NULL insulin-like growth factor-i mediated vasculogenesis/angiogenesis in human lung 
3 insulin-like growth factor-i receptor-mediated vasculogenesis in human lung development 
3 insulin-like growth factor-i receptor-mediated angiogenesis in human lung development 
2 vasculogenesis/angiogenesis in human lung development . NULL NULL NULL 
0 NULL NULL NULL the structural and functional development of 
2 the structural and functional development of the pulmonary system 
17 the pulmonary system is dependent upon appropriate early vascularization 
3 dependent upon appropriate early vascularization of the embryonic lung 
0 model indicated that insulin-like growth factor-i ( igf-i ) 
3 ) is a potent angiogenic agent for fetal lung 
0 NULL to assess its role on human vascular lung 
2 on human vascular lung development , we first examined 
9 we first examined the expression of igf-i/ii and igf 
0 NULL NULL NULL NULL immunohistochemical and in situ hybridization 
9 hybridization studies revealed the presence of igf-i/ii-igf-ir ligands and 
10 hybridization studies revealed the presence of igf-i/ii-igf-ir ligands and 
0 of igf-i/ii-igf-ir ligands and mrna transcripts in embryonic lungs 
0 lung explants demonstrated a significant blockade of igf-ir signaling 
18 explants demonstrated a significant blockade of igf-ir signaling . 
18 NULL NULL NULL NULL inactivation of igf-ir resulted in 
17 NULL inactivation of igf-ir resulted in a loss of 
18 igf-ir resulted in a loss of endothelial cells , 
16 , accompanied by dramatic changes in fetal lung explant 
19 and tem studies of treated lungs demonstrated numerous apoptotic 
2 system for lung vascular development . NULL NULL NULL 
9 first demonstration of igf-i/ii expression in the human lung 
0 the igf family of growth factors , acting through 
17 the igf-ir , is required as a survival factor 
0 is required as a survival factor during normal human 
3 during normal human lung vascularization . NULL NULL NULL 
17 NULL NULL NULL NULL enhanced expression of vascular endothelial 
9 NULL NULL NULL enhanced expression of vascular endothelial growth 
0 expression of vascular endothelial growth factor by periodontal pathogens 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
3 of vascular permeability and angiogenesis . NULL NULL NULL 
16 NULL NULL NULL NULL aberrant angiogenesis is often associated 
3 NULL NULL NULL aberrant angiogenesis is often associated with 
16 aberrant angiogenesis is often associated with lesion formation in 
2 often associated with lesion formation in chronic periodontitis . 
0 the aim of the present study was to investigate 
0 was to investigate the properties of vegf expression in 
9 the properties of vegf expression in human gingival fibroblasts 
0 fibroblasts ( hgf ) culture . NULL NULL NULL 
17 NULL NULL hgf were stimulated with lipopolysaccharide ( lps 
0 ) and outer membrane protein ( omp ) from 
9 NULL NULL hgf constitutively produced vegf and levels were 
0 constitutively produced vegf and levels were significantly enhanced ( 
17 and levels were significantly enhanced ( p less than 
17 than 0.01 ) by stimulation with ve and omp 
0 other hand , vegf levels were not increased by 
17 vegf levels were not increased by lps stimulation . 
0 not increased by lps stimulation . NULL NULL NULL 
0 NULL NULL NULL vegf mrna expression was also observed 
10 NULL NULL vegf mrna expression was also observed in 
0 mrna expression was also observed in ve- and omp-stimulated 
17 observed in ve- and stimulated hgf . NULL NULL 
17 NULL a vascular permeability enhancement ( vpe ) assay 
17 cultures of ve- and stimulated hgf enhance vascular permeability 
17 ve- and omp-stimulated hgf enhance vascular permeability in vivo 
17 cultures of ve- and stimulated hgf strongly induced vpe 
0 and omp-stimulated hgf strongly induced vpe . NULL NULL 
0 NULL this was markedly suppressed upon simultaneous injection of 
19 markedly suppressed upon simultaneous injection of anti-vegf polyclonal antibodies 
0 NULL heating and protease treatment of the stimulants reduced 
18 treatment of the stimulants reduced the vegf enhancing levels 
17 stimulants reduced the vegf enhancing levels in ve and 
0 reduced the vegf enhancing levels in ve and omp 
0 NULL NULL NULL these results suggest that ve and 
0 and omp may be crucial heat-labile and protease-sensitive components 
0 be crucial heat-labile and sensitive components of periodontal pathogens 
17 of periodontal pathogens that enhance vegf expression . NULL 
9 pathogens that enhance vegf expression . NULL NULL NULL 
0 NULL NULL NULL in addition , vegf might be 
0 , vegf might be associated with the etiology of 
3 early stages according to neovascularization stimulated by periodontal pathogens 
17 stages according to neovascularization stimulated by periodontal pathogens causing 
19 topical fluconazole and corticosteroid treatment for experimental candida albicans 
19 in candida albicans keratitis treated with fluconazole . NULL 
0 of 105 rabbits were infected with viable yeast cells 
19 groups of animals were treated for 21 days with 
0 i acting as a control , and groups ii 
0 groups ii to vii receiving adjunct therapy with the 
19 to vii receiving adjunct therapy with the corticosteroid prednisolone 
0 or 15 days after infection ) . NULL NULL 
14 the degree of corneal infiltration , ulceration , corneal 
3 hypopyon , conjunctivitis , neovascularization , and corneal perforation 
0 NULL NULL NULL NULL results : the control group 
0 NULL results : the control group showed the highest 
0 : the control group showed the highest level of 
3 of corneal clouding and neovascularization . NULL NULL NULL 
19 majority of groups also treated with prednisolone displayed significantly 
3 less corneal clouding and neovascularization . NULL NULL NULL 
0 NULL NULL an immediate decrease in corneal clouding was 
0 in corneal clouding was observed in groups treated with 
19 was observed in groups treated with additional low- or 
0 from day 9 after inoculation . NULL NULL NULL 
19 NULL after additional prednisolone treatment from day 9 or 
0 9 or 15 after inoculation , no significant difference 
0 after inoculation , no significant difference was detected in 
0 no significant difference was detected in the recultivation rate 
0 albicans compared with the control . NULL NULL NULL 
19 NULL NULL NULL early administration of prednisolone ( day 
0 and high dose ) resulted in the recultivation of 
19 plus adjunct high-dose prednisolone treatment was most effective when 
0 prednisolone treatment was most effective when administered 9 days 
0 was most effective when administered 9 days after infection 
0 administered 9 days after infection . NULL NULL NULL 
0 NULL NULL NULL the delayed application of corticosteroids after 
19 NULL NULL the delayed application of corticosteroids after treatment 
19 application of corticosteroids after treatment with antimycotic drugs in 
0 contraindicated and may be beneficial in patients . NULL 
0 NULL NULL NULL solid tumor therapy : manipulation of 
19 NULL NULL solid tumor therapy : manipulation of the 
16 solid tumor therapy : manipulation of the vasculature with 
0 NULL NULL NULL drug delivery to solid tumors is 
0 challenging aspects in cancer therapy . NULL NULL NULL 
0 the test tube , clinical trials often fail due 
0 test tube , clinical trials often fail due to 
0 unfavorable pharmacokinetics , poor delivery , low local concentrations 
0 local concentrations , and limited accumulation in the target 
0 concentrations , and limited accumulation in the target cell 
0 limited accumulation in the target cell . NULL NULL 
0 NULL NULL NULL a major step forwards in the 
19 step forwards in the treatment of solid tumors is 
0 the recognition of the associated vasculature as an important 
0 tumor-associated vasculature as an important target for therapy . 
0 vasculature as an important target for therapy . NULL 
0 an important target for therapy . NULL NULL NULL 
18 NULL NULL NULL NULL inhibition of tumor vascular development 
0 NULL NULL inhibition of tumor vascular development has a 
2 inhibition of tumor vascular development has a direct effect 
0 vascular development has a direct effect on the growth 
16 development has a direct effect on the growth and 
4 direct effect on the growth and progression of the 
2 on the growth and progression of the tumor . 
0 and progression of the tumor . NULL NULL NULL 
6 NULL NULL NULL NULL destruction of an existing vasculature 
6 also directly inflicts serious damage to the tumor cell 
0 serious damage to the tumor cell . NULL NULL 
0 NULL moreover , the tumor vascular bed can be 
0 can be manipulated facilitating enhanced permissiveness of the tumor 
0 enhanced permissiveness of the tumor for administered chemotherapeutics . 
19 of the tumor for administered chemotherapeutics . NULL NULL 
0 we focus on the use of tumor necrosis factor 
0 on the use of tumor necrosis factor alpha ( 
0 the use of tumor necrosis factor alpha ( tnf 
19 in local and systemic therapy in conjunction with chemotherapy 
0 therapy in conjunction with chemotherapy . NULL NULL NULL 
0 demonstrates potent and selective activity on the tumor vascular 
0 selective activity on the tumor vascular bed , which 
17 bed , which strongly improves tumor response . NULL 
0 , which strongly improves tumor response . NULL NULL 
0 which strongly improves tumor response . NULL NULL NULL 
0 of various biomaterials commonly used for inguinal hernia repair 
0 used for inguinal hernia repair have not been studied 
0 compare behavior and tissue response between two new polyester 
0 prostheses and a commonly used polypropylene ( pp ) 
0 space with a centrally placed single suture . NULL 
3 , foreign-body reaction , neovascularization , hemorrhage , necrosis 
5 neovascularization , hemorrhage , necrosis , and exudate . 
17 NULL NULL pp mesh resulted in more fibrous encapsulation 
17 NULL NULL pp also resulted in less connective tissue 
2 in less connective tissue formation and foreign-body reaction than 
5 in fat encapsulation , necrosis , hemorrhage , or 
16 NULL NULL NULL therapeutic targeting of the survivin pathway 
0 pathway in cancer : initiation of mitochondrial apoptosis and 
0 : initiation of mitochondrial apoptosis and suppression of tumor-associated 
18 of mitochondrial apoptosis and suppression of tumor-associated angiogenesis . 
0 apoptosis and suppression of tumor angiogenesis . NULL NULL 
0 apoptosis and suppression of associated angiogenesis . NULL NULL 
3 and suppression of tumor-associated angiogenesis . NULL NULL NULL 
0 molecular antagonists of the inhibitor of apoptosis protein survivin 
0 of the inhibitor of apoptosis protein survivin have shown 
0 the inhibitor of apoptosis protein survivin have shown promise 
0 anticancer strategies for triggering tumor cell apoptosis , dysregulating 
5 for triggering tumor cell apoptosis , dysregulating mitotic progression 
0 apoptosis , dysregulating mitotic progression , and inhibiting tumor 
18 mitotic progression , and inhibiting tumor growth in preclinical 
0 progression , and inhibiting tumor growth in preclinical models 
4 , and inhibiting tumor growth in preclinical models . 
5 couples to the cell death machinery has remained elusive 
0 and the relevant cellular targets of survivin antagonists have 
19 microvascular endothelial cells were infected with replication-deficient adenoviruses encoding 
0 cells were infected with deficient adenoviruses encoding survivin ( 
0 ) , green fluorescent protein ( pad-gfp ) , 
0 ) , or a phosphorylation survivin thr ( 34 
0 ) , or a defective survivin thr ( 34 
0 ( pad-t34a ) dominant negative mutant . NULL NULL 
16 NULL NULL NULL the effect of wild-type or mutant 
17 viability , and caspase activation in vitro and on 
0 and on kinetics of tumor growth and development of 
4 on kinetics of tumor growth and development of angiogenesis 
0 of tumor growth and development of angiogenesis in a 
3 growth and development of angiogenesis in a breast cancer 
5 NULL NULL the cell death pathway initiated by survivin 
17 the cell death pathway initiated by survivin targeting was 
19 pathway initiated by survivin targeting was mapped with respect 
14 respect to cytochrome c release , changes in mitochondrial 
0 cytochrome c release , changes in mitochondrial transmembrane potential 
0 changes in mitochondrial transmembrane potential , and apoptosome requirements 
9 using mouse embryonic fibroblasts deficient in apaf-1 or caspase-9 
0 NULL NULL NULL NULL results : adenoviral transduction of 
0 endothelial cells with pad-survivin inhibited growth factor deprivation- or 
0 cells with pad-survivin inhibited growth factor deprivation- or ceramide-induced 
0 growth factor deprivation- or induced apoptosis , reduced caspase-3 
0 factor deprivation- or ceramide-induced apoptosis , reduced caspase-3 and 
18 or ceramide-induced apoptosis , reduced caspase-3 and -7 generation 
9 reduced caspase-3 and -7 generation , and stabilized three-dimensional 
9 NULL NULL conversely , expression of pad-t34a caused apoptosis 
17 , expression of pad-t34a caused apoptosis in umbilical vein 
5 expression of pad-t34a caused apoptosis in umbilical vein and 
17 microvascular endothelial cells and resulted in caspase-3 activity . 
0 and resulted in caspase-3 activity . NULL NULL NULL 
5 NULL NULL NULL cell death induced by survivin targeting 
17 NULL NULL cell death induced by survivin targeting exhibited 
19 death induced by survivin targeting exhibited the hallmarks of 
0 induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent 
0 exhibited the hallmarks of dependent apoptosis with release of 
0 the hallmarks of mitochondrial-dependent apoptosis with release of cytochrome 
14 of mitochondrial-dependent apoptosis with release of cytochrome c and 
0 of cytochrome c and loss of mitochondrial transmembrane potential 
0 loss of mitochondrial transmembrane potential and was suppressed in 
0 transmembrane potential and was suppressed in apaf-1 or caspase-9 
19 NULL NULL NULL when injected in human breast cancer 
18 cancer xenografts , pad-t34a inhibited growth of established tumors 
4 xenografts , pad-t34a inhibited growth of established tumors and 
0 pad-t34a inhibited growth of established tumors and triggered tumor 
17 of established tumors and triggered tumor cell apoptosis in 
0 established tumors and triggered tumor cell apoptosis in vivo 
5 and triggered tumor cell apoptosis in vivo . NULL 
0 NULL NULL this was associated with a approximately 60 
18 a approximately 60 % reduction in tumor-derived blood vessels 
0 60 % reduction in derived blood vessels by quantitative 
0 quantitative morphometry of cd31-stained tumor areas , and appearance 
0 tumor areas , and appearance of endothelial cell apoptosis 
5 appearance of endothelial cell apoptosis by internucleosomal dna fragmentation 
0 NULL conclusions : survivin functions as a novel upstream 
0 as a novel upstream regulator of mitochondrial-dependent apoptosis , 
0 novel upstream regulator of dependent apoptosis , and molecular 
0 upstream regulator of mitochondrial-dependent apoptosis , and molecular targeting 
0 apoptosis , and molecular targeting of this pathway results 
0 targeting of this pathway results in anticancer activity via 
0 pathway results in anticancer activity via a dual mechanism 
0 activity via a dual mechanism of induction of tumor 
17 a dual mechanism of induction of tumor cell apoptosis 
0 mechanism of induction of tumor cell apoptosis and suppression 
5 induction of tumor cell apoptosis and suppression of angiogenesis 
18 tumor cell apoptosis and suppression of angiogenesis . NULL 
3 apoptosis and suppression of angiogenesis . NULL NULL NULL 
17 NULL NULL NULL ccl16 activates an angiogenic program in 
3 NULL ccl16 activates an angiogenic program in vascular endothelial 
0 ccl16 activates an angiogenic program in vascular endothelial cells 
16 NULL NULL NULL besides regulating leukocyte trafficking in normal 
14 NULL besides regulating leukocyte trafficking in normal and injured 
18 chemokines may positively or negatively regulate angiogenesis . NULL 
18 may positively or negatively regulate angiogenesis . NULL NULL 
3 positively or negatively regulate angiogenesis . NULL NULL NULL 
17 we report that ccl16 activates an angiogenic program in 
3 that ccl16 activates an angiogenic program in vascular endothelial 
0 ccl16 activates an angiogenic program in vascular endothelial cells 
17 vascular endothelial cells by activating ccr1 . NULL NULL 
17 NULL NULL NULL ccl16 induces dose-dependent random and directional 
0 NULL NULL ccl16 induces dependent random and directional migration 
14 dose-dependent random and directional migration of endothelial cells isolated 
0 migration of endothelial cells isolated from large vessels and 
1 capillaries without inducing their proliferation . NULL NULL NULL 
17 NULL NULL it also promotes endothelial differentiation into capillary-like 
2 it also promotes endothelial differentiation into capillary-like structures in 
3 vitro assay and is angiogenic in the chick chorionallantoic 
3 NULL NULL NULL these angiogenic activities are neutralized by 
0 NULL NULL these angiogenic activities are neutralized by a 
0 NULL NULL NULL the direct angiogenic activity of ccl16 
3 NULL NULL the direct angiogenic activity of ccl16 is 
0 NULL the direct angiogenic activity of ccl16 is further 
0 of ccl16 is further amplified by its ability to 
0 further amplified by its ability to prime endothelium to 
0 to a mitogen signal induced by vascular endothelial growth 
0 induced by vascular endothelial growth factor a and to 
9 to raise their basal production of cxcl8 and ccl2 
3 ccl2 , 2 other angiogenic chemokines . NULL NULL 
18 a ccr1 antagonist , inhibits angiogenic properties of ccl16 
3 ccr1 antagonist , inhibits angiogenic properties of ccl16 , 
0 antagonist , inhibits angiogenic properties of ccl16 , whereas 
18 of ccl16 , whereas blocking of ccr8 or desensitizing 
17 did not abolish endothelial activation . NULL NULL NULL 
0 ccl16 may be specifically linked to ccr1 expressed on 
9 specifically cross-linked to ccr1 expressed on endothelial cells . 
18 NULL NULL the largely restricted ccl16 expression in the 
9 the largely restricted ccl16 expression in the liver suggests 
16 that this chemokine may play a role in hepatic 
16 chemokine may play a role in hepatic vascular formation 
2 role in hepatic vascular formation during development and in 
0 hepatic vascular formation during development and in angiogenesis associated 
3 during development and in angiogenesis associated to hepatic diseases 
0 development and in angiogenesis associated to hepatic diseases . 
16 NULL autocrine angiotensin system regulation of bovine aortic endothelial 
14 bovine aortic endothelial cell migration and plasminogen activator involves 
0 cell migration and plasminogen activator involves modulation of proto-oncogene 
0 migration and plasminogen activator involves modulation of proto-oncogene pp60c-src 
16 and plasminogen activator involves modulation of proto-oncogene pp60c-src expression 
9 modulation of proto-oncogene pp60c-src expression . NULL NULL NULL 
14 NULL rapid endothelial cell migration and inhibition of thrombosis 
0 endothelial cell migration and inhibition of thrombosis are critical 
0 inhibition of thrombosis are critical for the resolution of 
0 for the resolution of denudation injuries to the vessel 
18 NULL NULL NULL NULL inhibition of the endothelial cell 
0 either the angiotensin-converting enzyme inhibitor lisinopril or the angiotensin 
0 , ile8-angiotensin ii , leads to increased endothelial cell 
17 ii , leads to increased endothelial cell migration and 
14 to increased endothelial cell migration and urokinase-like plasminogen activator 
0 migration and urokinase-like plasminogen activator ( u-pa ) activity 
0 activator ( u-pa ) activity ( bell , l. 
18 NULL NULL NULL NULL inhibition of the autocrine angiotensin 
0 system with the converting-enzyme inhibitor or the receptor antagonist 
0 the receptor antagonist also leads to increased expression of 
17 antagonist also leads to increased expression of the proto-oncogene 
9 also leads to increased expression of the proto-oncogene c-src 
0 proto-oncogene c-src : pp60c-src mrna increased 7-11-fold , c-src 
17 c-src : pp60c-src mrna increased 7-11-fold , c-src protein 
0 increased 7-11-fold , c-src protein 3-fold , and c-src 
0 , and c-src kinase activity 2-3-fold . NULL NULL 
9 NULL NULL endothelial cell expression of c-src was constitutively 
17 of c-src was constitutively elevated after stable infection with 
0 constitutively elevated after stable infection with a retroviral vector 
17 NULL NULL NULL constitutively increased c-src kinase activity reconstituted 
0 constitutively increased c-src kinase activity reconstituted the increases in 
0 increased c-src kinase activity reconstituted the increases in migration 
17 kinase activity reconstituted the increases in migration and u-pa 
0 reconstituted the increases in migration and u-pa observed with 
0 in migration and u-pa observed with angiotensin system interruption 
0 antisera to bovine u-pa blocked the increase in migration 
0 bovine u-pa blocked the increase in migration associated with 
0 blocked the increase in migration associated with increased c-src 
0 the increase in migration associated with increased c-src expression 
17 in migration associated with increased c-src expression . NULL 
9 associated with increased c-src expression . NULL NULL NULL 
17 these data suggest that increases in endothelial cell migration 
14 increases in endothelial cell migration and plasminogen activator after 
0 cell migration and plasminogen activator after angiotensin system inhibition 
18 activator after angiotensin system inhibition are at least partially 
16 at least partially pp60c-src mediated . NULL NULL NULL 
17 NULL NULL NULL NULL elevated c-src expression with angiotensin 
9 NULL NULL elevated c-src expression with angiotensin system inhibition 
18 expression with angiotensin system inhibition may act to enhance 
0 angiotensin system inhibition may act to enhance intimal wound 
0 inhibition may act to enhance intimal wound closure and 
0 to enhance intimal wound closure and to reduce luminal 
0 wound closure and to reduce luminal thrombogenicity in vivo 
0 NULL NULL cell type-specific regulation of angiogenic growth factor 
3 cell type-specific regulation of angiogenic growth factor gene expression 
0 type-specific regulation of angiogenic growth factor gene expression and 
0 angiogenic growth factor gene expression and induction of angiogenesis 
17 factor gene expression and induction of angiogenesis in nonischemic 
3 expression and induction of angiogenesis in nonischemic tissue by 
0 tissue by a constitutively active form of hypoxia-inducible factor 
0 by a constitutively active form of hypoxia-inducible factor 1 
0 constitutively active form of inducible factor 1 . NULL 
16 NULL understanding molecular mechanisms regulating angiogenesis may lead to 
3 understanding molecular mechanisms regulating angiogenesis may lead to novel 
0 mechanisms regulating angiogenesis may lead to novel therapies for 
0 may lead to novel therapies for ischemic disorders . 
0 NULL NULL NULL NULL inducible factor 1 ( hif-1 
17 1 ( hif-1 ) activates vascular endothelial growth factor 
0 ) activates vascular endothelial growth factor ( vegf ) 
9 ( vegf ) gene expression in hypoxic/ischemic tissue . 
19 study we demonstrate that exposure of primary cultures of 
0 adenovirus encoding a constitutively active form of hif-1alpha , 
0 encoding a constitutively active form of hif-1alpha , modulates 
16 form of hif-1alpha , modulates the expression of genes 
9 hif-1alpha , modulates the expression of genes encoding the 
3 of genes encoding the angiogenic factors angiopoietin-1 ( angpt1 
0 , angpt2 , placental growth factor , and platelet-derived 
0 growth factor , and derived growth factor-b . NULL 
0 factor , and platelet-derived growth factor-b . NULL NULL 
0 NULL NULL NULL NULL loss effects were also observed 
0 NULL NULL NULL NULL function effects were also observed 
0 NULL NULL NULL loss-of-function effects were also observed in 
0 loss-of-function effects were also observed in hif-1alpha-null embryonic stem 
0 were also observed in null embryonic stem cells . 
9 the cell type , expression of angpt1 and angpt2 
17 and angpt2 was either activated or repressed in response 
0 activated or repressed in response to hypoxia or adca5 
0 complete concordance between the effects of hypoxia and adca5 
19 NULL NULL NULL NULL injection of adca5 into mouse 
17 adca5 into mouse eyes induced neovascularization in multiple capillary 
3 into mouse eyes induced neovascularization in multiple capillary beds 
0 NULL analysis of gene expression revealed increased expression of 
17 of gene expression revealed increased expression of angpt1 , 
10 gene expression revealed increased expression of angpt1 , angpt2 
0 angpt1 , angpt2 , derived growth factor-b , placental 
0 , angpt2 , platelet-derived growth factor-b , placental growth 
0 growth factor-b , placental growth factor , and vegf 
0 factor , and vegf mrna in adca5-injected eyes . 
19 and vegf mrna in injected eyes . NULL NULL 
0 NULL NULL NULL these results indicate that hif-1 functions 
0 results indicate that hif-1 functions as a master regulator 
16 functions as a master regulator of angiogenesis by controlling 
3 a master regulator of angiogenesis by controlling the expression 
16 regulator of angiogenesis by controlling the expression of multiple 
0 angiogenesis by controlling the expression of multiple angiogenic growth 
3 the expression of multiple angiogenic growth factors and that 
0 expression of multiple angiogenic growth factors and that adenovirus-mediated 
0 growth factors and that mediated expression of a constitutively 
9 factors and that adenovirus-mediated expression of a constitutively active 
0 expression of a constitutively active form of hif-1alpha is 
0 of a constitutively active form of hif-1alpha is sufficient 
0 form of hif-1alpha is sufficient to induce angiogenesis in 
17 hif-1alpha is sufficient to induce angiogenesis in nonischemic tissue 
3 is sufficient to induce angiogenesis in nonischemic tissue of 
16 NULL NULL NULL differential regulation of in vivo angiogenesis 
3 regulation of in vivo angiogenesis by angiotensin ii receptors 
0 ii ) , a key regulator of blood pressure 
0 ) , a key regulator of blood pressure and 
16 homeostasis , exerts mitogenic effects on endothelial cells . 
16 ii could be a mediator between homeostatic changes within 
16 a mediator between homeostatic changes within the vascular perfusion 
0 changes within the vascular perfusion bed and growth factor-driven 
0 vascular perfusion bed and growth factor-driven angiogenesis . NULL 
3 bed and growth factor-driven angiogenesis . NULL NULL NULL 
0 NULL NULL in the present study , we applied 
3 applied the alginate implant angiogenesis model in mice with 
0 with normal ang ii levels , elevated ang ii 
17 ang ii levels , elevated ang ii levels by 
0 , elevated ang ii levels by transgenic overexpression of 
0 ang ii levels by transgenic overexpression of angiotensinogen ( 
9 ii levels by transgenic overexpression of angiotensinogen ( aogen 
9 , or in at2 deficient mice . NULL NULL 
18 we demonstrate that a decrease in the amount of 
0 in the amount of circulating ang ii by the 
0 enzyme ( ace ) inhibitor enalapril or the at1 
17 at1 receptor antagonist losartan induced a stimulation of in 
17 antagonist losartan induced a stimulation of in vivo angiogenesis 
3 stimulation of in vivo angiogenesis implying an inhibitory function 
0 vivo angiogenesis implying an inhibitory function of ang ii 
0 angiogenesis implying an inhibitory function of ang ii through 
17 however , the strong increase of angiogenesis in aogen-transgenic 
3 the strong increase of angiogenesis in aogen-transgenic mice compared 
0 increase of angiogenesis in transgenic mice compared with mice 
0 with normal ang ii levels suggests additional stimulatory activity 
0 ii levels suggests additional stimulatory activity . NULL NULL 
0 levels suggests additional stimulatory activity . NULL NULL NULL 
0 NULL NULL NULL we showed that the ang ii-induced 
17 showed that the ang induced stimulation of angiogenesis is 
17 that the ang ii-induced stimulation of angiogenesis is linked 
3 ang ii-induced stimulation of angiogenesis is linked to the 
0 stimulation of angiogenesis is linked to the at2 receptor 
18 at2 receptor as an impaired induction of angiogenesis was 
17 receptor as an impaired induction of angiogenesis was obtained 
3 an impaired induction of angiogenesis was obtained in at2 
0 induction of angiogenesis was obtained in at2 receptor knockout 
16 that the at2 receptor mediates a stimulation of in 
17 at2 receptor mediates a stimulation of in vivo angiogenesis 
3 stimulation of in vivo angiogenesis and indicate that ang 
0 ii is a humoral regulator of peripheral angiogenesis involving 
3 humoral regulator of peripheral angiogenesis involving two receptor subtypes 
0 regulator of peripheral angiogenesis involving two receptor subtypes with 
0 NULL NULL NULL NULL levels of expression of cyr61 
9 NULL NULL levels of expression of cyr61 and ctgf 
0 ctgf are prognostic for tumor progression and survival of 
2 are prognostic for tumor progression and survival of individuals 
5 for tumor progression and survival of individuals with gliomas 
0 NULL NULL the biological properties of ccn proteins include 
17 of ccn proteins include stimulation of cell proliferation , 
1 include stimulation of cell proliferation , migration , and 
14 of cell proliferation , migration , and adhesion , 
15 , migration , and adhesion , as well as 
3 , as well as angiogenesis and tumorigenesis . NULL 
0 wisp-1 , and nov mrna expression levels in samples 
10 , and nov mrna expression levels in samples from 
0 and nov mrna expression levels in samples from sixty-six 
9 explore the links between expression of the ccn genes 
0 the ccn genes and clinical and pathological parameters . 
9 NULL NULL NULL NULL overexpression of cyr61 , ctgf 
0 NULL NULL interestingly , significant associations were found between 
9 were found between cyr61 expression versus tumor grade , 
0 between cyr61 expression versus tumor grade , pathology , 
0 NULL also , a significant correlation existed between ctgf 
0 correlation existed between ctgf mrna levels versus tumor grade 
0 existed between ctgf mrna levels versus tumor grade , 
0 ctgf mrna levels versus tumor grade , gender , 
0 and ctgf , no significant association was found between 
0 ctgf , no significant association was found between expression 
9 association was found between expression of either wisp-1 or 
0 NULL furthermore , cox regression analysis showed that cyr61 
0 , cox regression analysis showed that cyr61 and ctgf 
9 that cyr61 and ctgf expression had a significant correlation 
0 ctgf expression had a significant correlation with patient survival 
5 significant correlation with patient survival . NULL NULL NULL 
0 NULL NULL NULL these results suggest that cyr61 and 
16 cyr61 and ctgf may play a role in the 
16 ctgf may play a role in the progression of 
2 a role in the progression of gliomas ; their 
0 of gliomas ; their levels at diagnosis may have 
0 might serve as valuable targets for therapeutic intervention . 
0 oxygen metabolism has an important role in the pathogenesis 
0 metabolism has an important role in the pathogenesis of 
0 important role in the pathogenesis of rheumatoid arthritis . 
8 species ( ros ) produced in the course of 
0 course of cellular oxidative phosphorylation , and by activated 
17 phosphorylation , and by activated phagocytic cells during oxidative 
8 NULL NULL the excessive production of ros can damage 
11 production of ros can damage protein , lipids , 
6 production of ros can damage protein , lipids , 
0 of ros can damage protein , lipids , nucleic 
0 nucleic acids , and matrix components . NULL NULL 
0 they also serve as important intracellular signaling molecules that 
0 that amplify the synovial proliferative response . NULL NULL 
0 amplify the synovial inflammatory-proliferative response . NULL NULL NULL 
0 of hypoxia and reoxygenation associated with changes in synovial 
0 and reoxygenation associated with changes in synovial perfusion are 
19 with changes in synovial perfusion are postulated to activate 
17 perfusion are postulated to activate hypoxia-inducible factor-1alpha and nuclear 
0 are postulated to activate inducible factor-1alpha and nuclear factor-kappab 
0 nuclear factor-kappab , two key transcription factors that are 
0 factor-kappab , two key transcription factors that are regulated 
16 transcription factors that are regulated by changes in cellular 
0 that are regulated by changes in cellular oxygenation and 
0 cellular oxygenation and cytokine stimulation , and that in 
0 in turn orchestrate the expression of a spectrum of 
0 a spectrum of genes critical to the persistence of 
0 understanding of the complex interactions involved in these pathways 
0 of the complex interactions involved in these pathways might 
0 interactions involved in these pathways might allow the development 
0 pathways might allow the development of novel therapeutic strategies 
0 NULL NULL NULL intrauterine growth restriction ( iugr ) 
0 the circulatory and transport properties of the sheep placenta 
0 which to study the development of iugr . NULL 
0 are those of hyperthermic exposure during pregnancy , and 
18 both models yield significantly reduced placental weights and an 
4 weights and an asymmetrically growth fetus , and display 
18 weights and an asymmetrically restricted fetus , and display 
0 fetus , and display altered maternal hormone concentrations , 
18 , indicative of an impaired trophoblast capacity . NULL 
18 NULL NULL additionally , impaired placental angiogenesis and uteroplacental 
3 additionally , impaired placental angiogenesis and uteroplacental blood flow 
16 NULL NULL NULL the effects of these alterations in 
16 the effects of these alterations in placental functional development 
2 alterations in placental functional development appear to be irreversible 
18 hypoglycaemic , and have reduced insulin and insulin-like growth 
0 reduced insulin and insulin-like growth factor-1 ( igf-1 ) 
17 igf-1 ) , and elevated concentrations of lactate . 
0 remain constant compared with control pregnancies . NULL NULL 
0 NULL NULL NULL NULL maintained utilization of these substrates 
0 substrates , in a deficient environment , suggests increased 
0 substrate-deficient environment , suggests increased sensitivities to metabolic signals 
0 increased sensitivities to metabolic signals , which may play 
0 signals , which may play a role in the 
0 which may play a role in the development of 
0 a role in the development of metabolic diseases in 
16 prospective study on the effect of zoledronic acid on 
18 zoledronic acid on the prevention of bone metastases in 
0 the prevention of bone metastases in patients with recurrent 
0 tumors that did not present with bone metastases at 
0 not present with bone metastases at baseline . NULL 
0 : bisphosphonates have been used successfully in the treatment 
19 used successfully in the treatment of hypercalcemia and to 
0 of hypercalcemia and to reduce skeletal-related complications of bone 
0 skeletal-related complications of bone metastases . NULL NULL NULL 
0 they may also have direct antitumor effects via induction 
0 also have direct antitumor effects via induction of apoptosis 
0 direct antitumor effects via induction of apoptosis , inhibition 
0 effects via induction of apoptosis , inhibition of the 
18 induction of apoptosis , inhibition of the invasive potential 
0 inhibition of the invasive potential of tumor cell lines 
0 the invasive potential of tumor cell lines in vitro 
18 lines in vitro , inhibition of angiogenesis , and 
3 vitro , inhibition of angiogenesis , and reduction in 
18 of angiogenesis , and reduction in tumor growth indirectly 
0 , and reduction in tumor growth indirectly via effects 
4 and reduction in tumor growth indirectly via effects on 
0 tumor growth indirectly via effects on accessory cells . 
16 study that examined the effect of preventive zoledronic acid 
19 of preventive zoledronic acid treatment on the development of 
2 acid treatment on the development of bone metastases in 
0 the development of bone metastases in patients with recurrent 
0 tumors , without bone metastases at the time of 
0 patients with recurrent or metastatic advanced cancer , without 
0 cancer , without bone metastases , were randomized into 
19 zoledronic acid or no treatment . NULL NULL NULL 
0 followed up until bone metastases were established . NULL 
0 until bone metastases were established . NULL NULL NULL 
0 NULL NULL NULL NULL results : the percentage of 
0 of patients being bone metastases free at 12 mo 
0 patients being bone metastases free at 12 mo was 
0 10 % in the control group ( p less 
0 NULL conclusions : the results have shown that bisphosphonates 
19 that bisphosphonates as adjuvant treatment might be useful for 
18 be useful for the prevention of bone metastases ; 
0 the prevention of bone metastases ; however , there 
19 in the meantime preventive use of bisphosphonates in patients 
0 patients without any bone metastases should not be used 
0 metastases should not be used outside the scope of 
0 the scope of a clinical trial . NULL NULL 
0 NULL NULL NULL NULL impaired coronary collateral vessel development 
2 impaired coronary collateral vessel development in patients with proliferative 
0 development in patients with proliferative diabetic retinopathy . NULL 
0 been reported to have impaired coronary collateral vessel growth 
4 impaired coronary collateral vessel growth , although they have 
3 although they have excessive neovascularization in the retina . 
0 ) in patients with proliferative diabetic retinopathy ( pdr 
0 in at least one major epicardial coronary artery were 
0 NULL serum vascular endothelial growth factor ( vegf ) 
0 factor ( vegf ) levels were measured using the 
0 were measured using the linked immunosorbent assay ( elisa 
0 NULL NULL NULL NULL results : the mean rentrop 
0 NULL NULL serum vegf levels were higher in patients 
0 ccc had similar vegf levels . NULL NULL NULL 
0 may have a different action on retinal and coronary 
14 NULL mechanisms of pericyte recruitment in tumour angiogenesis : 
3 pericyte recruitment in tumour angiogenesis : a new role 
0 angiogenesis : a new role for metalloproteinases . NULL 
17 blood vessels and are critical for the development of 
2 are critical for the development of a functional vascular 
19 NULL NULL NULL NULL targeting tumour pericytes is a 
3 pericytes is a promising angiogenic therapy but requires identifying 
18 is a promising anti-angiogenic therapy but requires identifying the 
0 promising anti-angiogenic therapy but requires identifying the mechanisms of 
14 the mechanisms of their recruitment in tumour and addressing 
0 NULL NULL among the pathways involved in pericyte recruitment 
0 NULL among the pathways involved in pericyte recruitment during 
14 pathways involved in pericyte recruitment during embryonic development , 
0 pericyte recruitment during embryonic development , the contribution of 
16 embryonic development , the contribution of platelet-derived growth factor 
0 , the contribution of derived growth factor b and 
0 the contribution of platelet-derived growth factor b and sphingosine 
3 is confirmed in tumour angiogenesis . NULL NULL NULL 
0 NULL NULL NULL the effect of angiopoietin 1 depends 
0 effect of angiopoietin 1 depends on the tumour model 
0 NULL NULL NULL transforming growth factor-beta1 enhances tumour vascularization 
17 NULL transforming growth factor-beta1 enhances tumour vascularization and microvessel 
3 growth factor-beta1 enhances tumour vascularization and microvessel maturation . 
2 tumour vascularization and microvessel maturation . NULL NULL NULL 
0 suggest a participation of matrix metalloproteinases ( mmp ) 
14 ) in tumour pericyte recruitment that is consistent with 
16 is consistent with the effect of certain mmps in 
2 certain mmps in the development of microvasculature in embryonic 
0 of microvasculature in embryonic development and in in vitro 
17 possibility for mmps to contribute to pericyte recruitment at 
14 to contribute to pericyte recruitment at six levels : 
0 pericyte recruitment at six levels : ( 1 ) 
0 : ( 1 ) direct promotion of pericyte invasion 
17 ( 1 ) direct promotion of pericyte invasion by 
14 direct promotion of pericyte invasion by extracellular matrix degradation 
0 pericyte invasion by extracellular matrix degradation ; ( 2 
6 invasion by extracellular matrix degradation ; ( 2 ) 
17 ; ( 2 ) stimulation of pericyte proliferation and 
1 ) stimulation of pericyte proliferation and protection against apoptosis 
0 of pericyte proliferation and protection against apoptosis by modification 
0 proliferation and protection against apoptosis by modification of the 
17 ; ( 3 ) activation of pericytes through the 
0 of pericytes through the release of growth factor bound 
0 through the release of growth factor bound to the 
15 release of growth factor bound to the ecm ; 
3 4 ) transactivation of angiogenic cell surface receptor ; 
3 5 ) propagation of angiogenic signalling as cofactor ; 
14 and ( 6 ) recruitment of bone marrow-derived stem 
0 ) recruitment of bone derived stem cells . NULL 
14 NULL NULL NULL ectopic localization of mitochondrial atp synthase 
16 atp synthase : a target for anti-angiogenesis intervention ? 
3 : a target for angiogenesis intervention ? NULL NULL 
17 this ectopic atp synthase catalyzes atp synthesis and is 
8 atp synthase catalyzes atp synthesis and is inhibited by 
18 atp synthesis and is inhibited by angiostatin over a 
1 NULL NULL endothelial cells grown at normal ph suffer 
0 ph suffer no ill effects from this angiostatin-mediated inhibition 
0 ill effects from this mediated inhibition of atp synthase 
18 effects from this angiostatin-mediated inhibition of atp synthase , 
1 , whereas endothelial cells grown at low , tumor-like 
18 NULL NULL NULL angiostatin inhibits both atp synthesis and 
8 angiostatin inhibits both atp synthesis and atp hydrolysis ( 
11 atp synthesis and atp hydrolysis ( moser et al. 
0 interferes with intracellular ph regulation ( wahl and grant 
19 NULL NULL although angiostatin administered intravenously is cleared from 
0 are more stable have potential for clinical application . 
0 stable have potential for clinical application . NULL NULL 
0 have potential for clinical application . NULL NULL NULL 
0 NULL NULL an angiostatin-mimetic activity has recently been observed 
0 activity has recently been observed using a polyclonal antibody 
0 order to explore the mechanism of action of angiostatin 
0 explore the mechanism of action of angiostatin and its 
0 be done to evaluate clinical applicability , specificity , 
16 NULL prostate-specific membrane antigen regulates angiogenesis by modulating integrin 
3 prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal 
16 antigen regulates angiogenesis by modulating integrin signal transduction . 
17 psma ) is universally upregulated in the vasculature of 
16 , but its functional role in tumor angiogenesis has 
0 its functional role in tumor angiogenesis has not been 
3 functional role in tumor angiogenesis has not been investigated 
3 here we show that angiogenesis is severely impaired in 
18 that angiogenesis is severely impaired in psma-null animals and 
0 is severely impaired in null animals and that this 
3 animals and that this angiogenic defect occurs at the 
14 level of endothelial cell invasion through the extracellular matrix 
0 invasion through the extracellular matrix barrier . NULL NULL 
6 NULL NULL because proteolytic degradation of the extracellular matrix 
0 degradation of the extracellular matrix is a critical component 
0 extracellular matrix is a critical component of endothelial invasion 
14 critical component of endothelial invasion in angiogenesis , it 
3 of endothelial invasion in angiogenesis , it is logical 
0 that psma participates in matrix degradation . NULL NULL 
6 psma participates in matrix degradation . NULL NULL NULL 
16 novel and more complex role for psma in angiogenesis 
3 role for psma in angiogenesis , where it is 
0 principal component of a regulatory loop that is tightly 
16 loop that is tightly modulating laminin-specific integrin signaling and 
0 laminin-specific integrin signaling and dependent , p21-activated kinase 1 
0 signaling and gtpase-dependent , activated kinase 1 ( pak-1 
0 1 ( pak-1 ) activity . NULL NULL NULL 
18 we show that psma inhibition , knockdown , or 
19 that psma inhibition , knockdown , or deficiency decreases 
9 , knockdown , or deficiency decreases endothelial cell invasion 
18 knockdown , or deficiency decreases endothelial cell invasion in 
16 knockdown , or deficiency decreases endothelial cell invasion in 
14 deficiency decreases endothelial cell invasion in vitro via integrin 
3 pak , thus abrogating angiogenesis . NULL NULL NULL 
18 1 ) or the inactivation of pak increases psma 
17 the inactivation of pak increases psma activity , suggesting 
0 of pak increases psma activity , suggesting that they 
18 , suggesting that they negatively regulate psma . NULL 
18 suggesting that they negatively regulate psma . NULL NULL 
18 NULL NULL NULL this negative regulation is mediated by 
18 NULL NULL this negative regulation is mediated by the 
16 this negative regulation is mediated by the cytoskeleton as 
18 the cytoskeleton as the disruption of interactions between the 
15 as the disruption of interactions between the psma cytoplasmic 
0 tail and the anchor protein filamin a decreases psma 
18 anchor protein filamin a decreases psma activity , integrin 
0 filamin a decreases psma activity , integrin function , 
0 psma activity , integrin function , and pak activation 
17 function , and pak activation . NULL NULL NULL 
18 NULL finally , the inhibition of pak activation enhances 
17 the inhibition of pak activation enhances the psma/filamin a 
17 inhibition of pak activation enhances the psma/filamin a interaction 
15 enhances the psma/filamin a interaction and , thus , 
0 thus , boosts psma activity . NULL NULL NULL 
0 autoregulatory loop , wherein active psma facilitates integrin signaling 
17 , wherein active psma facilitates integrin signaling and pak 
17 integrin signaling and pak activation , leading to both 
17 and pak activation , leading to both productive invasion 
0 leading to both productive invasion and downregulation of integrin 
18 both productive invasion and downregulation of integrin beta ( 
18 1 ) signaling via reduced psma activity . NULL 
0 signaling via reduced psma activity . NULL NULL NULL 
0 have identified a novel role for psma as a 
0 both extracellular and intracellular signals during angiogenesis . NULL 
3 and intracellular signals during angiogenesis . NULL NULL NULL 
3 porous plga microspheres for angiogenic growth factor delivery . 
0 plga microspheres for angiogenic growth factor delivery . NULL 
0 for angiogenic growth factor delivery . NULL NULL NULL 
14 were prepared for sustained release of basic fibroblast growth 
0 release of basic fibroblast growth factor ( bfgf ) 
17 ( bfgf ) to induce angiogenesis . NULL NULL 
3 bfgf ) to induce angiogenesis . NULL NULL NULL 
14 tested for in vitro release and in vivo angiogenic 
3 release and in vivo angiogenic activity . NULL NULL 
0 and in vivo angiogenic activity . NULL NULL NULL 
0 NULL NULL NULL NULL results : plga microspheres with 
0 an open-porous structure were formed . NULL NULL NULL 
14 NULL NULL plga-heparin microspheres released out bfgf in a 
0 smaller extent of initial burst than plga microspheres , 
16 that surface immobilized heparin controlled the release rate of 
14 immobilized heparin controlled the release rate of bfgf . 
19 NULL NULL NULL subcutaneous implantation of bfgf loaded plga-heparin 
17 microspheres in mice significantly induced the formation of new 
2 mice significantly induced the formation of new vascular microvessels 
0 open porous structure allowed significant amount of heparin immobilization 
0 bfgf loaded plga-hp microspheres showed sustained release profiles of 
14 plga-hp microspheres showed sustained release profiles of bfgf in 
15 demonstrating reversible and specific binding of bfgf to immobilized 
17 NULL NULL they also induced local angiogenesis in vivo 
3 they also induced local angiogenesis in vivo in an 
0 NULL NULL NULL the role of syndecans in disease 
9 heparan sulfate proteoglycans widely expressed in both developing and 
0 widely expressed in both developing and adult tissues . 
0 until recently , their role in pathogenesis was largely 
0 , their role in pathogenesis was largely unexplored . 
0 we discuss the reported involvement of syndecans in human 
3 , wound healing and angiogenesis . NULL NULL NULL 
9 some cancers , syndecan expression has been shown to 
16 has been shown to regulate tumor cell function ( 
0 been shown to regulate tumor cell function ( e.g. 
0 to regulate tumor cell function ( e.g. proliferation , 
1 cell function ( e.g. proliferation , adhesion , and 
15 ( e.g. proliferation , adhesion , and motility ) 
14 , adhesion , and motility ) and serve as 
0 a prognostic marker for tumor progression and patient survival 
2 prognostic marker for tumor progression and patient survival . 
5 tumor progression and patient survival . NULL NULL NULL 
0 of syndecans can also act as receptors/co-receptors for some 
0 and viral pathogens , mediating infection . NULL NULL 
0 viral pathogens , mediating infection . NULL NULL NULL 
0 NULL NULL NULL in addition , syndecans bind to 
15 in addition , syndecans bind to obesity-related factors and 
0 to obesity-related factors and regulate their signaling , in 
0 signaling , in turn modulating food consumption and weight 
0 also implicate syndecans in processes necessary for wound healing 
1 including fibroblast and endothelial proliferation , cell motility , 
14 endothelial proliferation , cell motility , angiogenesis , and 
3 , cell motility , angiogenesis , and extracellular matrix 
0 angiogenesis , and extracellular matrix organization . NULL NULL 
2 , and extracellular matrix organization . NULL NULL NULL 
0 new insights into the involvement of syndecans in disease 
7 in disease and tissue repair coupled with the emergence 
0 disease and tissue repair coupled with the emergence of 
0 syndecan-specific molecular tools may lead to novel therapies for 
0 may lead to novel therapies for a variety of 
16 NULL NULL NULL NULL role of the fibrinolytic and 
0 of the fibrinolytic and matrix metalloproteinase systems in development 
2 matrix metalloproteinase systems in development of adipose tissue . 
0 and cancer are a major cause of mortality and 
0 NULL NULL NULL NULL development of obesity is associated 
0 development of obesity is associated with extensive modifications in 
0 modifications in adipose tissue involving adipogenesis , angiogenesis and 
3 tissue involving adipogenesis , angiogenesis and extracellular matrix proteolysis 
0 , angiogenesis and extracellular matrix proteolysis . NULL NULL 
6 angiogenesis and extracellular matrix proteolysis . NULL NULL NULL 
0 ( plasminogen/plasmin ) and matrix metalloproteinase ( mmp ) 
0 systems cooperate in these processes . NULL NULL NULL 
0 NULL NULL a nutritionally induced obesity model in transgenic 
19 induced obesity model in transgenic mice has been used 
0 transgenic mice has been used extensively to study the 
0 extensively to study the role of the fibrinolytic and 
0 mmp systems in the development of obesity . NULL 
0 NULL NULL these studies support a role of both 
0 these studies support a role of both systems in 
0 and obesity ; the role of specific members of 
18 recombinant human prothrombin kringle-2 inhibits b16f10 melanoma metastasis through 
14 kringle-2 inhibits b16f10 melanoma metastasis through inhibition of neovascularization 
18 b16f10 melanoma metastasis through inhibition of neovascularization and reduction 
3 metastasis through inhibition of neovascularization and reduction of matrix 
18 inhibition of neovascularization and reduction of matrix metalloproteinase expression 
0 neovascularization and reduction of matrix metalloproteinase expression . NULL 
9 reduction of matrix metalloproteinase expression . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis , a multi-step process 
0 a multi-step process which involves endothelial cell proliferation , 
1 which involves endothelial cell proliferation , adhesion , migration 
15 endothelial cell proliferation , adhesion , migration , and 
14 proliferation , adhesion , migration , and basement membrane 
6 membrane ( bm ) degradation , is essential for 
17 ) degradation , is essential for tumor metastasis . 
0 , is essential for tumor metastasis . NULL NULL 
14 is essential for tumor metastasis . NULL NULL NULL 
18 kringle-2 ( rk-2 ) inhibited bovine capillary endothelial cell 
14 bovine capillary endothelial cell migration with an ic ( 
0 concentration for half maximal inhibition ) of 38 nm 
0 of 38 nm and inhibited adhesion to extracellular matrix 
0 38 nm and inhibited adhesion to extracellular matrix ( 
0 inhibited adhesion to extracellular matrix ( ecm ) proteins 
0 NULL NULL NULL because tumor metastasis requires angiogenesis , 
14 NULL NULL because tumor metastasis requires angiogenesis , we 
17 NULL because tumor metastasis requires angiogenesis , we examined 
3 because tumor metastasis requires angiogenesis , we examined whether 
18 examined whether rk-2 could inhibit metastases induced by injection 
0 whether rk-2 could inhibit metastases induced by injection of 
17 rk-2 could inhibit metastases induced by injection of b16f10 
19 inhibit metastases induced by injection of b16f10 melanoma cells 
0 NULL NULL NULL the results revealed that the metastatic 
14 results revealed that the metastatic tumors in mouse lung 
18 mouse lung were markedly decreased in a dose-dependent manner 
0 markedly decreased in a dependent manner and acute lung 
0 and acute lung injury induced by b16f10 melanoma metastasis 
14 induced by b16f10 melanoma metastasis was diminished by systemic 
0 b16f10 melanoma metastasis was diminished by systemic rk-2 treatment 
19 diminished by systemic rk-2 treatment . NULL NULL NULL 
0 NULL NULL NULL in immunohistochemical analysis , rk-2 reduced 
18 immunohistochemical analysis , rk-2 reduced expression of vascular endothelial 
9 analysis , rk-2 reduced expression of vascular endothelial growth 
0 expression of vascular endothelial growth factor , which is 
3 which is a potent angiogenic activator and neovascularization in 
0 is a potent angiogenic activator and neovascularization in the 
3 potent angiogenic activator and neovascularization in the mouse lung 
18 NULL also , rk-2 diminished the expression of matrix 
9 , rk-2 diminished the expression of matrix metalloproteinase-2 and 
0 diminished the expression of matrix metalloproteinase-2 and -9 in 
17 the mouse lung which induces tumor metastasis and angiogenesis 
0 mouse lung which induces tumor metastasis and angiogenesis . 
14 lung which induces tumor metastasis and angiogenesis . NULL 
3 induces tumor metastasis and angiogenesis . NULL NULL NULL 
18 these data suggest that inhibition of b16f10 melanoma metastasis 
14 inhibition of b16f10 melanoma metastasis by rk-2 was caused 
17 metastasis by rk-2 was caused by inhibition of neovascularization 
18 rk-2 was caused by inhibition of neovascularization and reduction 
3 caused by inhibition of neovascularization and reduction of matrix 
18 inhibition of neovascularization and reduction of matrix metalloproteinase expression 
0 neovascularization and reduction of matrix metalloproteinase expression . NULL 
9 reduction of matrix metalloproteinase expression . NULL NULL NULL 
0 NULL NULL NULL extracellular matrix as a bioactive material 
0 NULL NULL the extracellular matrix ( ecm ) directs 
0 material that can be used strategically to induce the 
17 be used strategically to induce the repair and restoration 
2 strategically to induce the repair and restoration of soft 
19 of soft tissues following surgery . NULL NULL NULL 
0 ) , which are derived from natural ecm , 
0 extracellular components necessary to direct the healing response , 
0 to direct the healing response , allow for the 
4 , allow for the proliferation of new , healthy 
0 tissue integrity to the damaged site . NULL NULL 
0 NULL NULL the 3-d organization of these extracellular components 
0 synthetic materials and is associated with constructive tissue remodelling 
3 ecm-assisted tissue remodelling include angiogenesis , recruitment of circulating 
14 remodelling include angiogenesis , recruitment of circulating progenitor cells 
0 angiogenesis , recruitment of circulating progenitor cells and constructive 
0 and constructive remodelling of damaged tissue structures . NULL 
0 NULL NULL the tissue response to this biologic mesh 
0 of recent reports on clinical hernia repair . NULL 
0 reports on clinical hernia repair . NULL NULL NULL 
0 [ study on the expression of angiogenesis and spontaneous 
3 on the expression of angiogenesis and spontaneous apoptosis and 
0 of angiogenesis and spontaneous apoptosis and their relevance in 
3 investigate the relationship among angiogenesis , spontaneous apoptosis and 
0 among angiogenesis , spontaneous apoptosis and clinicopathological parameters in 
0 ) and vascular endothelial growth factor ( vegf ) 
9 factor ( vegf ) expression were detected by immunohistochemistry 
0 vegf ) expression were detected by immunohistochemistry sabc and 
0 terminal uridine deoxynucleotidyl transferase mediated nick end labeling ( 
0 the average imvd in positive and negative cervical lymphatic 
0 imvd in positive and negative cervical lymphatic metastasis was 
0 and negative cervical lymphatic metastasis was ( 26.33 +/- 
0 and the imvd with positive lymphatic metastasis tumors was 
0 imvd with positive lymphatic metastasis tumors was statistical significantly 
0 higher than those with negative cervical lymphatic metastasis tumors 
0 with negative cervical lymphatic metastasis tumors ( p less 
9 NULL NULL NULL NULL expression of vegf had a 
0 vegf had a significantly positive correlation with imvd ( 
0 difference between imvd and tumor t-stage in lscc . 
0 imvd may be an important indicator to predict cervical 
0 to predict cervical lymphatic metastasis in lscc . NULL 
0 vegf might be an important angiogenic factor , and 
3 might be an important angiogenic factor , and could 
17 factor , and could promote tumor angiogenesis in lscc 
0 , and could promote tumor angiogenesis in lscc . 
3 and could promote tumor angiogenesis in lscc . NULL 
0 NULL NULL NULL NULL tumor angiogenesis might contribute to 
3 NULL NULL NULL tumor angiogenesis might contribute to tumor 
16 NULL tumor angiogenesis might contribute to tumor malignant progression 
0 angiogenesis might contribute to tumor malignant progression by inhibiting 
0 might contribute to tumor malignant progression by inhibiting spontaneous 
2 contribute to tumor malignant progression by inhibiting spontaneous apoptosis 
18 tumor malignant progression by inhibiting spontaneous apoptosis in lscc 
5 progression by inhibiting spontaneous apoptosis in lscc . NULL 
0 in particular , dynamic enhanced mri ( dce-mri ) 
3 evaluated before and after angiogenic treatment . NULL NULL 
19 before and after antiangiogenic treatment . NULL NULL NULL 
17 rats : tumours were induced by subcutaneous injection of 
19 were induced by subcutaneous injection of colon carcinoma cells 
0 NULL NULL NULL NULL perfusion and permeability parameters of 
19 permeability parameters of the implanted tumours were evaluated by 
0 gd-dtpa37-albumin ) to establish response to treatment with two 
19 to establish response to treatment with two different antiangiogenic 
3 treatment with two different angiogenic drugs ( tamoxifen and 
0 correlated with histology to obtain a radiological-histological map of 
0 NULL NULL NULL NULL results : dce-mri revealed greater 
0 : dce-mri revealed greater enhancement in the peripheral area 
0 area than in the central area in all the 
0 b22956/1 in the animals treated with the antiangiogenic drug 
3 animals treated with the angiogenic drug ( 0.0043317+/-0.0040418 ml/min 
0 significantly less than in untreated animals ( 0.0090460+/-0.0043680 ml/min 
0 ) , whereas no significant difference was observed with 
0 no significant difference was observed with gd-dtpa-albumin ( 13.14+/-13.94 
19 ( -1 ) in treated animals and 18.07+/-11.92 ml/min 
0 ( -1 ) in untreated animals ) . NULL 
0 , mean permeability and perfusion decreased by 51 % 
0 mean permeability and perfusion decreased by 51 % ( 
3 in all animals after angiogenic drug administration . NULL 
0 animals after antiangiogenic drug administration . NULL NULL NULL 
3 vascularity before and after angiogenic treatment . NULL NULL 
0 before and after antiangiogenic treatment . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis in the caprine caruncles 
19 and pregnant normal and treated does . NULL NULL 
0 of regular diameter and form , without crypts . 
0 complexity of the vasculature increased : at 4 weeks 
0 4 weeks the surface showed a pattern of ridges 
0 arteries penetrated the periphery forming an extensive mesh of 
2 NULL NULL capillary diameters increased significantly during pregnancy , 
0 weeks , when large flattened sinusoids formed . NULL 
0 when large flattened sinusoids formed . NULL NULL NULL 
0 of surface area for potential contact with the fetal 
0 surface area for potential contact with the fetal component 
0 usually considered to have increased interhemal distance compared with 
0 hemochorial types : our results suggest that the very 
2 that the very extensive development of sinusoids and crypts 
0 may compensate for any negative consequences of the placental 
3 NULL NULL NULL placental angiogenesis , which is physiologically 
0 circumstances , such as tumor . NULL NULL NULL 
16 NULL NULL NULL the effect of swainsonine ( active 
0 effect of swainsonine ( active compound of locoweed and 
0 of locoweed and a potential anticancer drug ) on 
2 drug ) on vascular development showed no differences in 
0 ) on vascular development showed no differences in sinusoidal 
18 weeks , but a decrease in capillary density was 
0 NULL NULL NULL swainsonine caused a great distortion to 
16 NULL NULL NULL the effects of this compound on 
2 compound on the vascular development lend credibility to its 
0 lend credibility to its potential as an anticancer agent 
3 carcinoma has a higher angiogenic activity than low-grade renal 
0 has a higher angiogenic activity than low-grade renal cell 
0 histomorphological quantification and qrt-pcr mrna expression profile . NULL 
0 quantification and qrt-pcr mrna expression profile . NULL NULL 
3 attractive disease to study angiogenesis and to test novel 
3 and to test novel angiogenesis inhibitors in early clinical 
0 angiogenesis inhibitors in early clinical development . NULL NULL 
0 inhibitors in early clinical development . NULL NULL NULL 
1 NULL NULL endothelial cell proliferation plays a pivotal role 
16 NULL endothelial cell proliferation plays a pivotal role in 
16 cell proliferation plays a pivotal role in the process 
16 proliferation plays a pivotal role in the process of 
3 in the process of angiogenesis . NULL NULL NULL 
3 study was to compare angiogenesis parameters in low nuclear 
0 panel of antibodies was used for immunohistochemistry : cd34/ki-67 
0 carbonic anhydrase ix , inducible factor-1alpha ( hif-1alpha ) 
0 ) and vascular endothelial growth factor ( vegf ) 
1 ) , endothelial cell proliferation fraction ( ecp % 
1 ) and tumour cell proliferation fraction ( tcp % 
0 NULL NULL NULL NULL mrna expression levels of angiogenesis 
0 NULL NULL NULL mrna expression levels of angiogenesis stimulators 
0 NULL NULL mrna expression levels of angiogenesis stimulators and 
3 mrna expression levels of angiogenesis stimulators and inhibitors were 
0 NULL NULL high-grade cc-rcc showed a higher ecp % 
0 , a higher vegf protein expression ( p less 
9 a higher vegf protein expression ( p less than 
0 and a lower hif-1alpha protein expression ( p=0.002 ) 
9 a lower hif-1alpha protein expression ( p=0.002 ) than 
0 NULL NULL NULL NULL growth factor mrna expression analyses 
0 NULL NULL growth factor mrna expression analyses revealed a 
0 NULL growth factor mrna expression analyses revealed a higher 
10 analyses revealed a higher expression of angiopoietin 2 in 
0 because of the imperfect association of nuclear grade and 
9 analysis revealed a higher expression of vessel maturation and 
2 higher expression of vessel maturation and stabilisation factors ( 
0 stabilisation factors ( placental growth factor , pdgfb1 , 
0 NULL NULL NULL our results suggest heterogeneity in angiogenic 
3 results suggest heterogeneity in angiogenic activity and vessel maturation 
0 suggest heterogeneity in angiogenic activity and vessel maturation of 
2 angiogenic activity and vessel maturation of cc-rcc , to 
0 to a large extent linked to nuclear grade , 
0 NULL NULL NULL the contribution of harold f . 
0 to the study of tumor angiogenesis and stroma generation 
3 the study of tumor angiogenesis and stroma generation mechanisms 
2 tumor angiogenesis and stroma generation mechanisms . NULL NULL 
0 first to show that tumor cells secreted vascular permeability 
14 show that tumor cells secreted vascular permeability factor ( 
0 ) and that a blocking antibody to vpf could 
18 antibody to vpf could prevent the edema and fluid 
0 the edema and fluid accumulation that is characteristic of 
14 demonstrate that vpf was secreted by a variety of 
0 a variety of human tumor cell lines and proposed 
0 vpf was in part responsible for the abnormal vasculature 
17 vpf was capable of stimulating endothelial cell growth and 
1 of stimulating endothelial cell growth and angiogenesis . NULL 
3 endothelial cell growth and angiogenesis . NULL NULL NULL 
0 NULL these fundamental discoveries led to additional research conducted 
0 vpf and renaming the protein vascular endothelial growth factor 
0 the protein vascular endothelial growth factor ( vegf ) 
17 secreting vpf , tumors induce angiogenesis by turning on 
3 vpf , tumors induce angiogenesis by turning on the 
0 on the wound healing response . NULL NULL NULL 
17 plasma fibrinogen , which stimulates blood vessel growth and 
4 which stimulates blood vessel growth and provides a matrix 
0 growth and provides a matrix on which they can 
0 on which they can spread . NULL NULL NULL 
9 that turn off vpf production after healing , tumors 
9 turn off their vpf production and instead continued to 
0 of vpf , allowing malignant cells to continue to 
17 cells to continue to induce new blood vessels and 
2 cells to continue to induce new blood vessels and 
1 vessels and so to grow and spread . NULL 
14 so to grow and spread . NULL NULL NULL 
0 work is again extremely significant for patients worldwide , 
0 's scientific research is leading his colleagues all over 
19 to examine how to treat a tumor through its 
0 how to treat a tumor through its blood supply 
0 hedgehog intercellular signaling pathway regulates cell proliferation and differentiation 
1 signaling pathway regulates cell proliferation and differentiation . NULL 
2 regulates cell proliferation and differentiation . NULL NULL NULL 
0 this pathway has been implicated to play a role 
0 has been implicated to play a role in the 
0 implicated to play a role in the pathogenesis of 
0 a role in the pathogenesis of cancer and in 
2 in embryonic blood vessel development . NULL NULL NULL 
0 , hedgehog signaling in tumor related vasculature and microenvironment 
0 NULL NULL NULL NULL use of exogenous sonic hedgehog 
17 shh ) peptide significantly increased brdu incorporation in endothelial 
14 peptide significantly increased brdu incorporation in endothelial cells in 
18 pathway antagonist cyclopamine effectively reduced shh-induced proliferation to control 
17 antagonist cyclopamine effectively reduced induced proliferation to control levels 
1 cyclopamine effectively reduced shh-induced proliferation to control levels . 
0 reduced shh-induced proliferation to control levels . NULL NULL 
0 shh-induced proliferation to control levels . NULL NULL NULL 
0 vivo a hind limb tumor model with the b16f0 
0 b16f0 cell line was used . NULL NULL NULL 
19 NULL NULL NULL NULL treatment with 25 mg/kg cyclopamine 
18 25 mg/kg cyclopamine significantly attenuated brdu incorporation in tumor 
14 cyclopamine significantly attenuated brdu incorporation in tumor cells threefold 
0 attenuated brdu incorporation in tumor cells threefold ( p 
0 0.001 ) , in tumor related endothelial cells threefold 
18 0.004 ) , and delayed tumor growth by 4 
0 ) , and delayed tumor growth by 4 days 
4 , and delayed tumor growth by 4 days . 
14 hedgehog receptor patched was localized to the tumor stroma 
0 was localized to the tumor stroma and that b16f0 
9 and that b16f0 cells expressed shh peptide . NULL 
0 , mouse embryonic fibroblasts required the presence of b16f0 
0 embryonic fibroblasts required the presence of b16f0 cells to 
9 of b16f0 cells to express patched in a co-culture 
0 express patched in a culture assay system . NULL 
9 indicate that shh peptide produced by melanoma cells induces 
17 produced by melanoma cells induces patched expression in fibroblasts 
9 melanoma cells induces patched expression in fibroblasts . NULL 
0 NULL NULL to study tumor related angiogenesis a vascular 
3 to study tumor related angiogenesis a vascular window model 
0 vascular window model was used to monitor tumor vascularity 
0 was used to monitor tumor vascularity . NULL NULL 
19 NULL NULL NULL NULL treatment with cyclopamine significantly attenuated 
18 treatment with cyclopamine significantly attenuated vascular formation by a 
2 cyclopamine significantly attenuated vascular formation by a factor of 
16 than 0.001 ) and altered vascular morphology . NULL 
0 NULL furthermore , cyclopamine reduced tumor blood vessel permeability 
0 furthermore , cyclopamine reduced tumor blood vessel permeability to 
19 vessel permeability to fitc labeled dextran while having no 
16 dextran while having no effect on normal blood vessels 
16 suggest that hedgehog signaling regulates melanoma related vascular formation 
2 regulates melanoma related vascular formation and function . NULL 
0 related vascular formation and function . NULL NULL NULL 
17 NULL NULL NULL NULL dependent subretinal microglia cell accumulation 
1 cx3cr1-dependent subretinal microglia cell accumulation is associated with cardinal 
16 microglia cell accumulation is associated with cardinal features of 
6 features of age-related macular degeneration . NULL NULL NULL 
16 NULL NULL NULL the role of retinal microglial cells 
6 ) in age-related macular degeneration ( amd ) is 
9 that all retinal mcs express cx3c chemokine receptor 1 
0 allele , which is associated with impaired cell migration 
18 which is associated with impaired cell migration , increases 
14 associated with impaired cell migration , increases the risk 
0 impaired cell migration , increases the risk of amd 
1 with amd , mcs accumulated in the subretinal space 
6 at sites of retinal degeneration and choroidal neovascularization ( 
3 retinal degeneration and choroidal neovascularization ( cnv ) . 
3 and choroidal neovascularization ( cnv ) . NULL NULL 
0 NULL NULL NULL in deficient mice , mcs accumulated 
1 cx3cr1-deficient mice , mcs accumulated subretinally with age and 
0 background and after laser impact preceding retinal degeneration . 
6 laser impact preceding retinal degeneration . NULL NULL NULL 
0 mice in the dark prevented both events . NULL 
0 NULL NULL NULL the appearance of lipid-bloated subretinal mcs 
17 senescent mice , and dependent mc accumulation was associated 
1 , and cx3cr1-dependent mc accumulation was associated with an 
16 cx3cr1-dependent mc accumulation was associated with an exacerbation of 
3 an exacerbation of experimental cnv . NULL NULL NULL 
0 NULL NULL NULL these results show that cx3cr1-dependent accumulation 
17 these results show that dependent accumulation of subretinal mcs 
1 results show that cx3cr1-dependent accumulation of subretinal mcs evokes 
0 novel pathogenic process with important implications for the development 
0 important implications for the development of new therapies for 
0 the development of new therapies for amd . NULL 
0 NULL NULL NULL [ clinical significance of interleukin-6 ( 
0 is proinflammatory cytokine that produces multifunctional effects . NULL 
0 cytokine that produces multifunctional effects . NULL NULL NULL 
0 NULL it is also involved in the regulation of 
0 also involved in the regulation of immune reactions , 
16 been shown to be associated with tumor progression including 
0 to be associated with tumor progression including inhibition of 
2 be associated with tumor progression including inhibition of cancer 
18 with tumor progression including inhibition of cancer cells apoptosis 
5 inhibition of cancer cells apoptosis and stimulation of angiogenesis 
17 cancer cells apoptosis and stimulation of angiogenesis . NULL 
3 apoptosis and stimulation of angiogenesis . NULL NULL NULL 
19 NULL NULL NULL anti-il-6 therapy is a new strategy 
0 NULL NULL NULL NULL clinical studies have shown elevated 
17 clinical studies have shown elevated serum il-6 concentrations in 
0 NULL NULL serum il-6 levels correlate with tumor stage 
0 il-6 levels correlate with tumor stage , and survival 
5 tumor stage , and survival of patients . NULL 
0 have focused on a role of il-6 as a 
16 human ovarian carcinoma : role in vasculogenic mimicry . 
0 and shows early extensive tumor invasion and peritoneal metastasis 
14 shows early extensive tumor invasion and peritoneal metastasis . 
14 tumor invasion and peritoneal metastasis . NULL NULL NULL 
4 vessels , intussusceptive microvascular growth , postnatal vasculogenesis , 
3 microvascular growth , postnatal vasculogenesis , glomeruloid angiogenesis and 
3 postnatal vasculogenesis , glomeruloid angiogenesis and vasculogenic mimicry ( 
0 NULL NULL vm is critical for a tumor blood 
0 is critical for a tumor blood supply and is 
0 with aggressive features and metastasis . NULL NULL NULL 
0 underlying significance of their ability to form vm in 
0 of their ability to form vm in vitro induced 
17 form vm in vitro induced by vegf-a . NULL 
0 the cancers with human embedded tumor tissue samples . 
0 cancers with human paraffin-embedded tumor tissue samples . NULL 
0 NULL NULL NULL NULL results show that the process 
3 main pathway for vm formation and vegf-a appears to 
16 and vegf-a appears to play an important role in 
16 appears to play an important role in the formation 
16 to play an important role in the formation of 
3 important role in the formation of vm based on 
0 in vitro assays and clinical immunohistochemical analyses . NULL 
0 vitro assays and clinical immunohistochemical analyses . NULL NULL 
16 NULL NULL NULL NULL targeting strategies for ovarian cancer 
19 ovarian cancer include anti-vegf-a treatment , knocking down the 
0 human mmps if the tumor is vm positive . 
0 the tumor is vm positive . NULL NULL NULL 
0 strategy may be of significant value in laying the 
3 a more explicit anti-tumor angiogenesis therapy . NULL NULL 
18 more explicit anti-tumor angiogenesis therapy . NULL NULL NULL 
0 NULL NULL a novel role of thrombospondin-1 in cervical 
0 of thrombospondin-1 in cervical carcinogenesis : inhibit stroma reaction 
18 in cervical carcinogenesis : inhibit stroma reaction by inhibiting 
18 inhibit stroma reaction by inhibiting activated fibroblasts from invading 
17 stroma reaction by inhibiting activated fibroblasts from invading cancer 
3 -1 , a potent angiogenesis inhibitor , has been 
0 , a potent angiogenesis inhibitor , has been shown 
0 to exert different biological functions on various cell types 
16 , we investigate the role of tsp-1 in tumor-stroma 
0 role of tsp-1 in tumor reaction , which is 
17 mainly characterized by fibroblast activation to create a permissive 
0 a permissive microenvironment for tumor progression . NULL NULL 
2 permissive microenvironment for tumor progression . NULL NULL NULL 
0 examinations in the human surgical specimens have shown that 
18 have shown that a downregulation of tsp-1 during the 
0 of tsp-1 during the progression of cervical carcinogenesis was 
0 the progression of cervical carcinogenesis was accompanied by an 
17 an emergence in the upregulation of stroma markers , 
19 NULL NULL NULL NULL transfection of siha cervical cancer 
9 cells with a plasmid expressing the tsp-1 protein exhibited 
0 plasmid expressing the tsp-1 protein exhibited antiangiogenic activity in 
0 expressing the tsp-1 protein exhibited antiangiogenic activity in vitro 
3 the tsp-1 protein exhibited angiogenic activity in vitro and 
18 tsp-1 protein exhibited antiangiogenic activity in vitro and resulted 
17 activity in vitro and resulted in reduced tumor growth 
18 vitro and resulted in reduced tumor growth in severe 
0 and resulted in reduced tumor growth in severe combined 
4 resulted in reduced tumor growth in severe combined immunodeficiency 
18 was accompanied by a decrease in tumor vascularization and 
0 by a decrease in tumor vascularization and lower expressions 
3 a decrease in tumor vascularization and lower expressions of 
9 tumor vascularization and lower expressions of alpha-sma and desmin 
0 those in the vector controls . NULL NULL NULL 
19 NULL NULL NULL NULL transfection with tsp-1 and purified 
0 transfection with tsp-1 and purified tsp-1 added to nih3t3 
19 tsp-1 and purified tsp-1 added to nih3t3 cells did 
16 nih3t3 cells did not alter the protein levels of 
0 did not alter the protein levels of alpha-sma and 
0 not alter the protein levels of alpha-sma and desmin 
18 and desmin but significantly inhibited matrix metalloprotease-2 activity . 
0 desmin but significantly inhibited matrix metalloprotease-2 activity . NULL 
0 significantly inhibited matrix metalloprotease-2 activity . NULL NULL NULL 
0 NULL NULL NULL transforming growth factor-beta ( tgf-beta ) 
0 tgf-beta ) , a major factor in the activation 
17 major factor in the activation of fibroblasts , increased 
17 activation of fibroblasts , increased alpha-sma and desmin expression 
9 increased alpha-sma and desmin expression and the ability of 
0 desmin expression and the ability of cell migration and 
14 the ability of cell migration and invasion in nih3t3 
14 of cell migration and invasion in nih3t3 cells . 
17 NULL NULL NULL the increased migration ability and the 
14 NULL NULL the increased migration ability and the invasive 
0 NULL the increased migration ability and the invasive ability 
0 ability and the invasive ability into tumor cluster of 
0 the invasive ability into tumor cluster of tgf-beta-treated nih3t3 
19 into tumor cluster of treated nih3t3 cells were dose 
18 cells were dose dependently inhibited by tsp-1 . NULL 
9 contrast , ectopic tsp-1 expression in siha cells has 
16 siha cells has little effect on the invasive ability 
0 effect on the invasive ability of the nih3t3 cells 
16 findings demonstrate a novel role of tsp-1 to inhibit 
18 role of tsp-1 to inhibit tumor-stroma reaction that could 
0 of tsp-1 to inhibit tumor reaction that could be 
17 to the blockage of activated fibroblasts from invading cancer 
0 colorectal cancer occurs after surgery and is based on 
0 the extent of disease invasiveness and dissemination . NULL 
0 of disease invasiveness and dissemination . NULL NULL NULL 
0 NULL NULL NULL NULL surgery is the primary treatment 
0 surgery is the primary treatment for stage i disease 
19 NULL NULL NULL adjuvant chemotherapy is recommended after resection 
0 chemotherapy is recommended after resection in selected high-risk patients 
0 NULL NULL convenience of administration , tolerability , and 
0 in decisions about adjuvant therapy after resection . NULL 
0 about adjuvant therapy after resection . NULL NULL NULL 
19 NULL NULL NULL NULL treatment of stage iv colorectal 
0 the type of prior therapy and patient-specific factors . 
0 NULL NULL recently , significant improvements in survival have 
0 , significant improvements in survival have been achieved through 
0 been achieved through the use of combination chemotherapy and 
0 the use of combination chemotherapy and monoclonal antibody regimens 
19 bevacizumab in combination with chemotherapy is first-line therapy for 
0 with chemotherapy is first-line therapy for stage iv disease 
0 should not preclude the use of chemotherapy in stage 
19 preclude the use of chemotherapy in stage iv colorectal 
0 cancer , although the ability to tolerate drug-related toxicity 
19 the optimal duration of chemotherapy in patients with early 
0 patients with early and metastatic colorectal cancer is unclear 
19 optimal approach to the treatment of colorectal cancer depends 
0 treatment of colorectal cancer depends on several considerations , 
0 NULL serum and urine levels of interleukin-8 in patients 
3 NULL NULL NULL NULL angiogenesis plays an important role 
16 NULL NULL NULL angiogenesis plays an important role in 
16 NULL angiogenesis plays an important role in many types 
16 angiogenesis plays an important role in many types of 
3 be a pro-inflammatory and angiogenic cytokine , and il-8 
16 been reported to be associated with tumor progression , 
0 to be associated with tumor progression , prognosis and 
2 be associated with tumor progression , prognosis and survival 
0 progression , prognosis and survival in several types of 
16 NULL however , the role of il-8 in non-hodgkin 
0 serum and urine il-8 levels in patients with nhl 
0 NULL NULL NULL we developed reference intervals for serum 
0 il-8 level in 131 control individuals . NULL NULL 
0 il-8 and urine il-8 levels in patients with nhl 
0 concentrations with those of control individuals . NULL NULL 
0 in patients than in controls ( 48.9+/-194.4 vs. 5.2+/-13.8 
0 , there were no significant differences in serum il-8 
0 between nhl patients and controls ( 159.2+/-40.4 vs. 99.6+/-107.1 
0 concentrations of il-8 and clinical variables , the only 
0 ipi ) , which showed a marginal correlation with 
0 correlation with urine il-8/cr levels ( p=0.07 ) . 
0 indicated that urine il-8/cr levels might be useful as 
17 the detection of nitric dependent angiogenesis in an animal 
3 detection of nitric oxide-dependent angiogenesis in an animal model 
0 oxide ( no ) plays an important role in 
0 no ) plays an important role in maintaining vascular 
0 ) plays an important role in maintaining vascular homeostasis 
0 an important role in maintaining vascular homeostasis . NULL 
0 such as vascular endothelial growth factor ( vegf ) 
17 factor ( vegf ) induced angiogenesis . NULL NULL 
3 ( vegf ) -induced angiogenesis . NULL NULL NULL 
0 one of the main contributing factors for angiogenesis . 
3 main contributing factors for angiogenesis . NULL NULL NULL 
0 several methods have been used for measuring in vitro 
3 for measuring in vitro angiogenesis , a proper technique 
0 technique has not been developed for identifying in vivo 
17 for identifying in vivo dependent angiogenesis . NULL NULL 
3 identifying in vivo no-dependent angiogenesis . NULL NULL NULL 
17 for detecting and measuring dependent angiogenesis in a mouse 
3 detecting and measuring no-dependent angiogenesis in a mouse model 
0 NULL NULL this technique showed strong abdominal neovascularization in 
3 technique showed strong abdominal neovascularization in wild-type mice , 
19 knockout mice , locally injected with vegf , as 
17 , as well as stimulation of angiogenesis in no 
3 well as stimulation of angiogenesis in no donor-injected mice 
19 of angiogenesis in no injected mice . NULL NULL 
18 technique also revealed the inhibitory effect of the nos 
18 also revealed the inhibitory effect of the nos inhibitor 
0 effect of the nos inhibitor n ( g ) 
17 g ) -iminoethyl-l-ornithine in mediated in vivo angiogenesis . 
3 in vegf-mediated in vivo angiogenesis . NULL NULL NULL 
17 imaging technique for detecting dependent angiogenesis in an animal 
3 technique for detecting no-dependent angiogenesis in an animal model 
17 receptor ( p75ntr ) promotes endothelial cell apoptosis and 
5 ) promotes endothelial cell apoptosis and inhibits angiogenesis : 
18 endothelial cell apoptosis and inhibits angiogenesis : implications for 
3 cell apoptosis and inhibits angiogenesis : implications for diabetes-induced 
0 angiogenesis : implications for induced impaired neovascularization in ischemic 
18 : implications for diabetes-induced impaired neovascularization in ischemic limb 
3 implications for diabetes-induced impaired neovascularization in ischemic limb muscles 
18 NULL NULL NULL diabetes impairs endothelial function and reparative 
0 NULL diabetes impairs endothelial function and reparative neovascularization . 
3 endothelial function and reparative neovascularization . NULL NULL NULL 
0 , which is scarcely present in healthy endothelial cells 
9 ) , becomes strongly expressed by capillary ecs after 
0 by capillary ecs after induction of peripheral ischemia in 
17 we show that gene induced p75 ( ntr ) 
9 p75 ( ntr ) expression impairs the survival , 
18 ( ntr ) expression impairs the survival , proliferation 
5 ) expression impairs the survival , proliferation , migration 
1 impairs the survival , proliferation , migration , and 
14 survival , proliferation , migration , and adhesion capacities 
15 , migration , and adhesion capacities of cultured ecs 
19 and adhesion capacities of cultured ecs and endothelial progenitor 
18 ( epcs ) and inhibits angiogenesis in vitro . 
3 epcs ) and inhibits angiogenesis in vitro . NULL 
14 ( ntr ) gene delivery impairs neovascularization and blood 
18 ntr ) gene delivery impairs neovascularization and blood flow 
3 ) gene delivery impairs neovascularization and blood flow recovery 
0 NULL NULL these disturbed functions are associated with suppression 
0 these disturbed functions are associated with suppression of signaling 
0 functions are associated with suppression of signaling mechanisms implicated 
0 suppression of signaling mechanisms implicated in ec survival and 
5 mechanisms implicated in ec survival and angiogenesis . NULL 
3 in ec survival and angiogenesis . NULL NULL NULL 
18 vegf-a/akt/enos/no pathway and additionally reduces the mrna levels of 
0 and additionally reduces the mrna levels of itgb1 [ 
0 additionally reduces the mrna levels of itgb1 [ beta 
0 , which typically show impaired postischemic muscular neovascularization and 
3 show impaired postischemic muscular neovascularization and blood perfusion recovery 
0 muscular neovascularization and blood perfusion recovery , have these 
0 recovery , have these defects corrected by intramuscular gene 
0 transfer of a dominant negative mutant form of p75 
0 a dominant negative mutant form of p75 ( ntr 
3 data newly demonstrate the angiogenic action of p75 ( 
18 newly demonstrate the antiangiogenic action of p75 ( ntr 
0 avenues for the therapeutic use of p75 ( ntr 
18 p75 ( ntr ) inhibition to combat diabetes-induced microvascular 
17 ) inhibition to combat induced microvascular liabilities . NULL 
0 NULL NULL NULL NULL tumor endothelial cell targeted cyclic 
19 NULL tumor endothelial cell targeted cyclic rgd-modified heparin derivative 
18 rgd-modified heparin derivative : inhibition of angiogenesis and tumor 
3 derivative : inhibition of angiogenesis and tumor growth . 
0 inhibition of angiogenesis and tumor growth . NULL NULL 
4 of angiogenesis and tumor growth . NULL NULL NULL 
0 purpose : we prepared tumor endothelium targeted crgd-modified heparin 
19 we prepared tumor endothelium targeted crgd-modified heparin derivative ( 
18 crgdyk , and evaluated inhibition effects of crgd-hl on 
0 , and evaluated inhibition effects of crgd-hl on angiogenesis 
3 effects of crgd-hl on angiogenesis and tumor growth . 
0 crgd-hl on angiogenesis and tumor growth . NULL NULL 
4 on angiogenesis and tumor growth . NULL NULL NULL 
3 methods : to evaluate angiogenic activity of crgd-hl , 
18 : to evaluate antiangiogenic activity of crgd-hl , we 
15 tests on endothelial cell adhesion and migration to vitronectin 
14 endothelial cell adhesion and migration to vitronectin , tube 
2 to vitronectin , tube formation , binding affinity to 
15 , tube formation , binding affinity to purified alpha 
0 tube formation , binding affinity to purified alpha ( 
0 , binding affinity to purified alpha ( v ) 
18 NULL NULL the antitumor activity of crgd-hl was also 
0 also evaluated by monitoring tumor growth and microvessel formation 
4 evaluated by monitoring tumor growth and microvessel formation in 
2 tumor growth and microvessel formation in squamous cell carcinoma 
0 carcinoma ( scc7 ) tumor . NULL NULL NULL 
0 NULL NULL NULL NULL results : the crgd-hl significantly 
18 : the crgd-hl significantly inhibited adhesion and migration of 
15 the crgd-hl significantly inhibited adhesion and migration of endothelial 
14 significantly inhibited adhesion and migration of endothelial cells to 
15 , crgd-hl has high binding affinity to purified alpha 
0 crgd-hl has high binding affinity to purified alpha ( 
0 high binding affinity to purified alpha ( v ) 
17 NULL NULL NULL the enhanced antiangiogenic effect of crgd-hl 
3 NULL NULL the enhanced angiogenic effect of crgd-hl was 
18 NULL the enhanced antiangiogenic effect of crgd-hl was confirmed 
0 assay by showing the significant inhibition of bfgf-driven angiogenesis 
18 by showing the significant inhibition of bfgf-driven angiogenesis and 
3 significant inhibition of bfgf-driven angiogenesis and blood vessel formation 
2 angiogenesis and blood vessel formation . NULL NULL NULL 
3 was thought that potent angiogenic effect of crgd-hl was 
18 thought that potent antiangiogenic effect of crgd-hl was probably 
18 probably due to the interference of alpha ( v 
0 beta ( 3 ) mediated interaction , resulting in 
15 ( 3 ) -mediated interaction , resulting in the 
0 ) -mediated interaction , resulting in the enhanced antitumoral 
17 , resulting in the enhanced antitumoral activity against scc7 
0 in the enhanced antitumoral activity against scc7 tumor . 
0 antitumoral activity against scc7 tumor . NULL NULL NULL 
0 NULL conclusion : these results demonstrated that crgd-modified heparin 
17 that crgd-modified heparin derivative enhanced anti-angiotherapeutic effects against solid 
18 heparin derivative enhanced anti-angiotherapeutic effects against solid tumor , 
0 anti-angiotherapeutic effects against solid tumor , and therefore , 
19 could be applied to treat various cancers and angiogenic 
3 treat various cancers and angiogenic diseases as a potent 
3 diseases as a potent angiogenesis inhibitor . NULL NULL 
0 as a potent angiogenesis inhibitor . NULL NULL NULL 
0 NULL NULL NULL [ inhibitory effect of adenovirus-mediated endostatin 
0 NULL NULL [ inhibitory effect of adenovirus-mediated endostatin gene 
17 [ inhibitory effect of mediated endostatin gene transfer on 
19 endostatin gene transfer on transplanted lung carcinoma in mice 
16 : to investigate the effect of adenovirus-mediated endostatin gene 
17 investigate the effect of mediated endostatin gene transfer on 
19 endostatin gene transfer on transplanted lung cancer in mice 
0 in mice and its mechanism of action . NULL 
0 and its mechanism of action . NULL NULL NULL 
19 NULL NULL methods : transplant tumor model was induced 
0 NULL methods : transplant tumor model was induced by 
0 transplant tumor model was induced by subcutaneous inoculation of 
19 was induced by subcutaneous inoculation of 2 x 10 
0 NULL the mice were treated by intratumoral injection of 
19 were treated by intratumoral injection of 2 x 10 
9 NULL NULL NULL the expression of endostatin in situ 
0 in situ and its maintaining time were detected by 
0 its maintaining time were detected by immunohistochemistry and western 
18 by elisa . the inhibition of tumor growth and 
0 . the inhibition of tumor growth and changes of 
4 the inhibition of tumor growth and changes of survival 
0 of tumor growth and changes of survival were recorded 
0 growth and changes of survival were recorded and the 
0 NULL NULL NULL the tumor apoptosis was observed by 
5 NULL NULL the tumor apoptosis was observed by electron 
0 the tumor apoptosis was observed by electron microscopy . 
0 NULL NULL NULL NULL results : in comparison with 
0 : in comparison with controls , intratumoral injection of 
19 with controls , intratumoral injection of ad-mendostatin significantly inhibited 
18 injection of ad-mendostatin significantly inhibited the tumor growth and 
0 ad-mendostatin significantly inhibited the tumor growth and metastasis , 
4 significantly inhibited the tumor growth and metastasis , and 
14 the tumor growth and metastasis , and prolonged the 
17 and metastasis , and prolonged the survival rate of 
5 , and prolonged the survival rate of mice ( 
0 NULL NULL NULL strong positive expression of mendostatin was 
9 NULL NULL strong positive expression of mendostatin was seen 
0 was seen in the tumor tissue after injection of 
19 the tumor tissue after injection of ad-mendostatin , immunhistochemically 
0 antibody , while the control groups showed only very 
0 while the control groups showed only very low expression 
9 showed only very low expression or absence . NULL 
19 the second week of administration , the expression of 
9 of administration , the expression of endostatin diminished a 
18 the expression of endostatin diminished a month later . 
18 ( mvd ) ) decreased from 42.4 +/- 4.8 
0 microscopic field by cd10 staining and from 68.5 +/- 
0 +/- 4.6 by cd31 staining , respectively ( p 
0 NULL NULL more apoptotic tumor cells were seen under 
19 conclusion : endostatin gene therapy mediated by adenoviral vector 
17 : endostatin gene therapy mediated by adenoviral vector efficiently 
17 by adenoviral vector efficiently induces expression of endostatin in 
9 adenoviral vector efficiently induces expression of endostatin in vivo 
18 in vivo , and inhibits the growth and metastasis 
4 , and inhibits the growth and metastasis of tumor 
14 inhibits the growth and metastasis of tumor . NULL 
0 growth and metastasis of tumor . NULL NULL NULL 
16 is concluded that its action is targeted to tumor 
0 that its action is targeted to tumor neovasculature and 
0 action is targeted to tumor neovasculature and the mechanism 
0 tumor neovasculature and the mechanism is inhibition of tumor 
18 and the mechanism is inhibition of tumor angiogenesis . 
0 mechanism is inhibition of tumor angiogenesis . NULL NULL 
3 is inhibition of tumor angiogenesis . NULL NULL NULL 
0 diverse cell signaling events modulated by perlecan . NULL 
0 ubiquitous pericellular proteoglycan ideally placed to mediate cell signaling 
0 proteoglycan ideally placed to mediate cell signaling events controlling 
0 mediate cell signaling events controlling migration , proliferation , 
0 cell signaling events controlling migration , proliferation , and 
0 events controlling migration , proliferation , and differentiation . 
0 , proliferation , and differentiation . NULL NULL NULL 
0 NULL NULL NULL its control of growth factor signaling 
0 NULL its control of growth factor signaling usually involves 
0 growth factor signaling usually involves interactions with the heparan 
0 factor signaling usually involves interactions with the heparan sulfate 
0 heparan sulfate chains covalently coupled to the protein core 
0 covalently coupled to the protein core 's n-terminus . 
0 however , this modular protein core also binds with 
0 modular protein core also binds with relatively high affinity 
0 binds with relatively high affinity to a number of 
0 to a number of growth factors and surface receptors 
0 surface receptors , thereby stabilizing cell-matrix links . NULL 
0 receptors , thereby stabilizing matrix links . NULL NULL 
0 review will focus on growth factor interactions and describe 
15 focus on perlecan-growth factor interactions and describe recent advances 
0 highly conserved proteoglycan during development , cancer growth , 
4 during development , cancer growth , and angiogenesis . 
3 cancer growth , and angiogenesis . NULL NULL NULL 
3 NULL NULL NULL the angiogenic capacities of perlecan that 
0 capacities of perlecan that involve proliferative and migratory signals 
0 of perlecan that involve proliferative and migratory signals in 
0 involve proliferative and migratory signals in response to bound 
0 and migratory signals in response to bound growth factors 
15 signals in response to bound growth factors will be 
0 in response to bound growth factors will be explored 
3 as well as the angiogenic signals resulting from interactions 
18 well as the anti-angiogenic signals resulting from interactions between 
17 as the anti-angiogenic signals resulting from interactions between the 
15 anti-angiogenic signals resulting from interactions between the c-terminal domain 
16 endorepellin and integrins that control adhesion of cells to 
15 and integrins that control adhesion of cells to the 
0 cells to the extracellular matrix . NULL NULL NULL 
0 two somewhat diametrically opposed roles will be discussed in 
0 on perlecan as a key regulator of cell growth 
0 perlecan as a key regulator of cell growth and 
1 key regulator of cell growth and angiogenesis . NULL 
3 of cell growth and angiogenesis . NULL NULL NULL 
0 NULL [ retinochoroidopathy after intravitreal anti-vegf treatment ] NULL 
0 retinochoroidopathy after intravitreal anti-vegf treatment ] NULL NULL NULL 
19 eye 2 weeks after intravitreal injection of bevacizumab to 
19 2 weeks after intravitreal injection of bevacizumab to treat 
19 injection of bevacizumab to treat choroidal neovascularization due to 
3 bevacizumab to treat choroidal neovascularization due to exudative age-related 
6 to exudative age-related macular degeneration . NULL NULL NULL 
0 of sarcoidosis , possibly resulting from an intravitreal injection 
19 possibly resulting from an intravitreal injection of bevacizumab . 
19 resulting from an intravitreal injection of bevacizumab . NULL 
19 NULL NULL the patient received a prescription for 100 
0 of the condition was observed . NULL NULL NULL 
14 NULL silencing of directional migration in roundabout4 knockdown endothelial 
0 directional migration in roundabout4 knockdown endothelial cells . NULL 
16 recently been identified to play a role in vascular 
16 identified to play a role in vascular guidance as 
19 we have investigated gene knockdown analysis of endothelial robos 
0 NULL NULL NULL NULL results : robo1 and robo4 
0 : robo1 and robo4 knockdown cells display distinct activity 
0 knockdown cells display distinct activity in endothelial cell migration 
14 activity in endothelial cell migration assay . NULL NULL 
19 NULL NULL NULL the knockdown of robo4 abrogated the 
18 the knockdown of robo4 abrogated the chemotactic response of 
16 robo4 abrogated the chemotactic response of endothelial cells to 
17 cells to serum but enhanced a chemokinetic response to 
16 but enhanced a chemokinetic response to slit2 , while 
0 slit2 , while robo1 knockdown cells do not display 
16 do not display chemotactic response to serum or vegf 
0 NULL NULL NULL robo4 knockdown endothelial cells unexpectedly show 
17 cells unexpectedly show up regulation of rho gtpases . 
18 gtpase homeostasis and serum reduced chemotaxis in robo4 knockdown 
14 homeostasis and serum reduced chemotaxis in robo4 knockdown cells 
0 reduced chemotaxis in robo4 knockdown cells . NULL NULL 
0 NULL NULL NULL in addition , this study mechanistically 
17 the signaling nexus between activated cdc42 and mena , 
0 been shown to be involved with robo4 signaling in 
14 together to guide directional migration of endothelial cells . 
17 NULL p53 hot-spot mutants increase tumor vascularization via ros-mediated 
0 p53 hot-spot mutants increase tumor vascularization via ros-mediated activation 
3 hot-spot mutants increase tumor vascularization via ros-mediated activation of 
17 increase tumor vascularization via mediated activation of the hif1/vegf-a 
17 tumor vascularization via ros-mediated activation of the hif1/vegf-a pathway 
0 NULL NULL NULL the function of p53 tumor suppressor 
0 the function of p53 tumor suppressor is often altered 
0 function of p53 tumor suppressor is often altered in 
0 tumor suppressor is often altered in various human tumors 
0 tumors predominantly through missense-mutations resulting in accumulation of mutant 
0 through missense-mutations resulting in accumulation of mutant proteins . 
9 NULL we revealed that expression of p53 proteins with 
17 various human tumors , increased the number of vessels 
17 as a result , accelerated their growth . NULL 
4 result , accelerated their growth . NULL NULL NULL 
17 NULL NULL NULL NULL stimulation of tumor angiogenesis was 
0 NULL NULL stimulation of tumor angiogenesis was connected with 
3 NULL stimulation of tumor angiogenesis was connected with about 
17 connected with about 2-fold increase in intracellular level of 
18 n-acetyl-l-aspartate ( nac ) decreased vessels number in tumors 
2 vessels number in tumors formed by cells with inactivated 
18 with inactivated p53 and inhibited their growth . NULL 
4 p53 and inhibited their growth . NULL NULL NULL 
16 NULL NULL NULL NULL effect of ros on angiogenesis 
3 effect of ros on angiogenesis in tumors expressing hot-spot 
9 on angiogenesis in tumors expressing hot-spot p53 mutants was 
0 was correlated with their ability to increase a content 
17 with their ability to increase a content of hif1 
0 a content of hif1 transcriptional factor responsible for up-regulation 
16 of hif1 transcriptional factor responsible for up-regulation of vegf-a 
17 transcriptional factor responsible for up-regulation of vegf-a mrnas . 
17 NULL NULL NULL estradiol increases il-8 secretion of normal 
14 NULL estradiol increases il-8 secretion of normal human breast 
16 or cxcl8 has been associated with tumor angiogenesis , 
0 has been associated with tumor angiogenesis , metastasis , 
3 been associated with tumor angiogenesis , metastasis , and 
14 with tumor angiogenesis , metastasis , and poor prognosis 
17 NULL NULL estrogen is crucial in breast carcinogenesis and 
0 is crucial in breast carcinogenesis and tumor progression . 
0 in breast carcinogenesis and tumor progression . NULL NULL 
2 breast carcinogenesis and tumor progression . NULL NULL NULL 
16 NULL whether sex steroids affect il-8 secretion of normal 
14 sex steroids affect il-8 secretion of normal breast tissue 
16 NULL NULL hence , regulatory mechanisms of il-8 need 
0 NULL NULL NULL we used microdialysis to sample il-8 
0 NULL we found a significant positive correlation between il-8 
0 we found a significant positive correlation between il-8 and 
0 normal breast tissue and dependent breast cancer in vivo 
19 ex vivo , estradiol exposure increased the il-8 secretion 
17 vivo , estradiol exposure increased the il-8 secretion of 
14 exposure increased the il-8 secretion of normal whole breast 
19 whole breast tissue in culture . NULL NULL NULL 
17 breast cancer , estradiol increased il-8 whereas the anti-estrogen 
18 whereas the anti-estrogen tamoxifen inhibited the secretion of il-8 
14 anti-estrogen tamoxifen inhibited the secretion of il-8 both in 
18 NULL an anti-il-8 ab inhibited endothelial cell proliferation induced 
1 ab inhibited endothelial cell proliferation induced by cancer cell 
17 inhibited endothelial cell proliferation induced by cancer cell produced 
9 induced by cancer cell produced il-8 and tumors with 
0 tumors with low il-8 levels exhibited decreased angiogenesis . 
0 with low il-8 levels exhibited decreased angiogenesis . NULL 
18 low il-8 levels exhibited decreased angiogenesis . NULL NULL 
3 il-8 levels exhibited decreased angiogenesis . NULL NULL NULL 
0 NULL NULL NULL our results strongly suggest that estradiol 
16 that estradiol has a critical role in the regulation 
16 estradiol has a critical role in the regulation of 
16 critical role in the regulation of il-8 in normal 
0 NULL NULL il-8 may present a novel therapeutic target 
0 present a novel therapeutic target for estrogen driven breast 
0 for estrogen driven breast carcinogenesis and tumor progression . 
0 driven breast carcinogenesis and tumor progression . NULL NULL 
2 breast carcinogenesis and tumor progression . NULL NULL NULL 
16 NULL NULL NULL NULL effect of estrogen and progesterone 
17 and progesterone on macrophage activation during wound healing . 
0 NULL NULL NULL age-related impaired wound healing leads to 
0 age-related impaired wound healing leads to substantial morbidity and 
6 evidence that the tissue damage associated with chronic wounds 
0 that the tissue damage associated with chronic wounds is 
17 with chronic wounds is initiated and propagated by an 
0 an inappropriately excessive inflammatory response . NULL NULL NULL 
0 NULL research on age-related impaired wound healing suggests that 
0 healing suggests that the decline in sex steroid hormones 
0 may have a substantial influence on the inflammatory response 
0 influence on the inflammatory response in vivo . NULL 
19 topical and systemic estrogen treatments have shown an increased 
0 treatments have shown an increased rate of healing by 
0 rate of healing by reducing inflammation , however the 
0 also suggest progesterone may play a role in modulating 
0 progesterone may play a role in modulating inflammation . 
0 play a role in modulating inflammation . NULL NULL 
0 NULL NULL macrophages are essential mediators of inflammation and 
17 NULL macrophages can be activated in a classical or 
16 out to investigate the roles of estrogen and progesterone 
17 and progesterone on macrophage activation during the wound healing 
0 during the wound healing response . NULL NULL NULL 
18 findings suggest with a reduction of steroid hormones following 
17 following ovariectomy , alternatively activated macrophage markers ( fizz1 
18 and ym1 ) were reduced , with this effect 
0 reduced , with this effect being reversed with the 
18 with this effect being reversed with the administration of 
19 being reversed with the administration of estrogen or progesterone 
18 suggesting that with the reduction of steroid hormones macrophages 
17 steroid hormones macrophages are activated in a classical manner 
0 a classical manner , promoting inflammation , whereas estrogen 
16 estrogen or progesterone are contributing toward macrophage activation in 
17 are contributing toward macrophage activation in an alternative manner 
0 manner , driving wound repair , angiogenesis , and 
3 driving wound repair , angiogenesis , and remodeling . 
0 , angiogenesis , and remodeling . NULL NULL NULL 
0 NULL NULL NULL NULL effect of platelet-rich plasma and 
0 glue on healing of critical calvarial bone defects . 
0 of critical-size calvarial bone defects . NULL NULL NULL 
0 including high amounts of growth factors is introduced to 
0 factors is introduced to clinical use rapidly . NULL 
0 is introduced to clinical use rapidly . NULL NULL 
16 was to compare the effects of prp and platelet-poor 
0 ) on healing of critical bone defects.bilateral full-thickness , 
0 bone defects.bilateral full-thickness , critical bone defects were created 
0 full-thickness , critical-size bone defects were created in the 
0 applied to the created defects before closure . NULL 
0 the created defects before closure . NULL NULL NULL 
0 radiologic defect area measurement results at 0 , 4 
0 NULL NULL NULL in addition , densities of the 
2 densities of the newly formed bones at 16th week 
3 secondary bone trabecula , neovascularization , and bone marrow 
2 marrow and connective tissue formation ) were compared between 
0 and 16-week groups.more rapid decrease in defect size was 
0 in defect size was observed in groups 3 and 
2 NULL NULL NULL newly formed bone densities were also 
2 NULL NULL new bone formation was detected to be 
0 new bone formation was detected to be more rapid 
16 ppp might have favorable effects on bone healing . 
0 2 substances considering osteoinductive potential , prp group has 
0 group has demonstrated superior results compared with fibrin glue 
0 platelet concentrations may expose beneficial effects of prp . 
0 concentrations may expose beneficial effects of prp . NULL 
0 NULL NULL NULL NULL derived angiopoietin-2 affects early stages 
16 NULL NULL host-derived angiopoietin-2 affects early stages of tumor 
0 affects early stages of tumor development and vessel maturation 
2 early stages of tumor development and vessel maturation but 
2 tumor development and vessel maturation but is dispensable for 
0 for later stages of tumor growth . NULL NULL 
4 later stages of tumor growth . NULL NULL NULL 
16 receptor tyrosine kinase system controlling vessel assembly , maturation 
2 kinase system controlling vessel assembly , maturation , and 
2 controlling vessel assembly , maturation , and quiescence . 
17 ang-2 ) is prominently up-regulated in the host-derived vasculature 
0 prominently up-regulated in the derived vasculature of most tumors 
3 an attractive candidate for angiogenic intervention . NULL NULL 
0 net outcome of ang-2 functions on tumor angiogenesis is 
0 of ang-2 functions on tumor angiogenesis is believed to 
3 ang-2 functions on tumor angiogenesis is believed to be 
0 correspondingly , ang-2 manipulatory therapies have been shown to 
0 as well as antitumorigenic effects . NULL NULL NULL 
16 NULL to clarify the role of ang-2 for angiogenesis 
3 role of ang-2 for angiogenesis and tumor growth in 
0 ang-2 for angiogenesis and tumor growth in a definite 
4 for angiogenesis and tumor growth in a definite genetic 
0 experimental setting , the present study was aimed at 
4 at comparatively studying the growth of different tumors in 
9 tumors in wild-type and deficient mice . NULL NULL 
4 and b16f10 melanomas all grew slower in ang-2-deficient mice 
9 all grew slower in deficient mice . NULL NULL 
0 NULL NULL yet , tumor growth in wild-type and 
4 NULL yet , tumor growth in wild-type and ang-2-deficient 
9 growth in wild-type and deficient mice dissociated during early 
0 during early stages of tumor development , whereas tumor 
2 early stages of tumor development , whereas tumor growth 
0 tumor development , whereas tumor growth rates during later 
4 development , whereas tumor growth rates during later stages 
0 later stages of primary tumor progression were similar . 
2 stages of primary tumor progression were similar . NULL 
0 vascular architecture revealed no major differences in microvessel density 
14 in microvessel density and perfusion characteristics . NULL NULL 
4 were smaller in tumors grown in ang-2-deficient mice , 
9 in tumors grown in deficient mice , and the 
0 the vasculature had an altered pattern of pericyte recruitment 
14 altered pattern of pericyte recruitment and maturation . NULL 
2 of pericyte recruitment and maturation . NULL NULL NULL 
9 NULL NULL NULL NULL deficient tumor vessels had higher 
0 NULL NULL NULL ang-2-deficient tumor vessels had higher pericyte 
14 NULL NULL NULL NULL recruited pericytes were desmin and 
0 were desmin and ng2 positive and predominately alpha-smooth muscle 
0 predominately alpha-smooth muscle actin negative , indicative of a 
16 the experiments define the role of ang-2 during tumor 
0 role of ang-2 during tumor angiogenesis and establish a 
3 of ang-2 during tumor angiogenesis and establish a better 
0 better rationale for combination therapies involving ang-2 manipulatory therapies 
0 rationale for combination therapies involving ang-2 manipulatory therapies . 
0 therapies involving ang-2 manipulatory therapies . NULL NULL NULL 
0 NULL NULL short pigment derived factor-derived peptide inhibits angiogenesis 
0 NULL short pigment epithelial-derived derived peptide inhibits angiogenesis and 
18 pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth 
3 epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth . 
0 peptide inhibits angiogenesis and tumor growth . NULL NULL 
4 inhibits angiogenesis and tumor growth . NULL NULL NULL 
0 NULL purpose : pigment derived factor ( pedf ) 
3 ) is a potent angiogenesis inhibitor with multiple other 
0 is a potent angiogenesis inhibitor with multiple other functions 
0 inhibitor with multiple other functions , some of which 
17 , some of which enhance tumor growth . NULL 
0 some of which enhance tumor growth . NULL NULL 
4 of which enhance tumor growth . NULL NULL NULL 
3 previous studies mapped pedf angiogenic and prosurvival activities to 
18 pedf antiangiogenic and prosurvival activities to distinct epitopes . 
3 pedf , which maintains angiogenic and antitumor efficacy . 
18 maintains antiangiogenic and antitumor efficacy . NULL NULL NULL 
0 hydrophilicity , and charge distribution of the angioinhibitory epitope 
0 NULL we analyzed their ability to block endothelial cell 
18 analyzed their ability to block endothelial cell chemotaxis and 
14 to block endothelial cell chemotaxis and induce apoptosis in 
17 endothelial cell chemotaxis and induce apoptosis in vitro and 
5 cell chemotaxis and induce apoptosis in vitro and their 
3 in vitro and their angiogenic activity in vivo . 
18 vitro and their antiangiogenic activity in vivo . NULL 
18 tested for the antitumor activity against mildly aggressive xenografted 
0 as pedf , we used immunohistochemistry to measure pedf 
0 immunohistochemistry to measure pedf targets , vascular endothelial growth 
0 targets , vascular endothelial growth factor receptor 2 , 
9 , and cd95 ligand expression in p18-treated vasculature . 
19 cd95 ligand expression in treated vasculature . NULL NULL 
0 NULL NULL NULL NULL results : p14 and p18 
18 : p14 and p18 blocked endothelial cell chemotaxis ; 
14 p18 blocked endothelial cell chemotaxis ; p18 and p23 
17 ; p18 and p23 induced apoptosis . NULL NULL 
5 p18 and p23 induced apoptosis . NULL NULL NULL 
0 NULL NULL NULL p18 showed the highest ic50 and 
18 the highest ic50 and blocked angiogenesis in vivo : 
3 highest ic50 and blocked angiogenesis in vivo : p23 
3 inactive and p14 was angiogenic . NULL NULL NULL 
17 NULL NULL NULL p18 increased the production of cd95 
9 NULL p18 increased the production of cd95 ligand and 
18 of cd95 ligand and reduced the expression of vascular 
9 ligand and reduced the expression of vascular endothelial growth 
0 expression of vascular endothelial growth factor receptor 2 by 
0 NULL NULL NULL in tumor studies , p18 was 
0 , p18 was more effective in blocking the angiogenesis 
18 was more effective in blocking the angiogenesis and growth 
3 effective in blocking the angiogenesis and growth of the 
4 blocking the angiogenesis and growth of the prostate cancer 
18 carcinoma , p18 strongly decreased angiogenesis and halted the 
3 , p18 strongly decreased angiogenesis and halted the progression 
17 angiogenesis and halted the progression of established tumors . 
0 halted the progression of established tumors . NULL NULL 
3 a novel and potent angiogenic biotherapeutic agent that has 
0 biotherapeutic agent that has potential to be developed for 
0 has potential to be developed for the treatment of 
19 be developed for the treatment of prostate and renal 
0 NULL NULL NULL distinct role of plcbeta3 in vegf-mediated 
16 role of plcbeta3 in mediated directional migration and vascular 
0 plcbeta3 in vegf-mediated directional migration and vascular sprouting . 
2 directional migration and vascular sprouting . NULL NULL NULL 
1 NULL NULL endothelial cell proliferation and migration is essential 
14 endothelial cell proliferation and migration is essential to angiogenesis 
17 proliferation and migration is essential to angiogenesis . NULL 
3 migration is essential to angiogenesis . NULL NULL NULL 
1 NULL NULL typically , proliferation and chemotaxis of endothelial 
14 typically , proliferation and chemotaxis of endothelial cells is 
0 cells is driven by growth factors such as vascular 
0 such as vascular endothelial growth factor ( vegf ) 
0 ) and basic fibroblast growth factor ( bfgf ) 
17 NULL NULL NULL vegf activates phospholipases ( plcs ) 
17 plcgamma1 - that are important for tubulogenesis , differentiation 
0 important for tubulogenesis , differentiation and dna synthesis . 
0 , differentiation and dna synthesis . NULL NULL NULL 
17 specifically through vegfr2 , induces phosphorylation of two serine 
16 specifically through vegfr2 , induces phosphorylation of two serine 
12 through vegfr2 , induces phosphorylation of two serine residues 
19 NULL NULL NULL NULL knockdown of plcbeta3 in huvec 
16 plcbeta3 in huvec cells affects ip3 production , actin 
9 huvec cells affects ip3 production , actin reorganization , 
16 ip3 production , actin reorganization , migration and proliferation 
14 , actin reorganization , migration and proliferation ; whereas 
1 reorganization , migration and proliferation ; whereas migration is 
14 and proliferation ; whereas migration is inhibited , proliferation 
18 ; whereas migration is inhibited , proliferation is enhanced 
1 migration is inhibited , proliferation is enhanced . NULL 
17 inhibited , proliferation is enhanced . NULL NULL NULL 
0 our data suggest that enhanced proliferation is precipitated by 
0 data suggest that enhanced proliferation is precipitated by an 
0 is precipitated by an accelerated cell cycle , and 
0 cell cycle , and decreased migration by an inability 
0 cycle , and decreased migration by an inability to 
17 by an inability to activate cdc42 . NULL NULL 
0 NULL NULL NULL NULL given that plcbeta3 is typically 
0 unique crosstalk between the protein and receptor tyrosine kinase 
0 reveal a novel molecular mechanism of vegf signaling and 
3 and , thus , angiogenesis . NULL NULL NULL 
0 NULL antivascular actions of binding drugs . NULL NULL 
0 NULL NULL NULL NULL binding drugs ( mbd ) 
0 mbd ) are widely used in cancer chemotherapy and 
19 widely used in cancer chemotherapy and also have clinically 
3 also have clinically relevant angiogenic and vascular-disrupting properties . 
6 clinically relevant antiangiogenic and disrupting properties . NULL NULL 
18 relevant antiangiogenic and vascular-disrupting properties . NULL NULL NULL 
0 due in part to direct effects on endothelial cells 
16 in part to direct effects on endothelial cells , 
0 all mbds ( both stabilizing and microtubule-destabilizing ) inhibit 
18 microtubule-stabilizing and microtubule-destabilizing ) inhibit endothelial cell proliferation , 
1 ) inhibit endothelial cell proliferation , migration , and 
14 endothelial cell proliferation , migration , and tube formation 
2 migration , and tube formation in vitro , actions 
3 to correspond to therapeutic angiogenic actions . NULL NULL 
0 NULL NULL NULL in addition , the microtubule-destabilizing agents 
16 microtubule-destabilizing agents cause prominent changes in endothelial cell morphology 
0 cell morphology , an action associated with rapid vascular 
16 morphology , an action associated with rapid vascular collapse 
6 associated with rapid vascular collapse in vivo . NULL 
16 NULL NULL NULL the effects on endothelial cells occur 
16 , which do not affect microtubule gross morphology , 
6 microtubule bundling or microtubule loss and do not induce 
0 loss and do not induce cell cycle arrest , 
0 not induce cell cycle arrest , apoptosis , or 
5 cell cycle arrest , apoptosis , or cell death 
5 apoptosis , or cell death . NULL NULL NULL 
0 low concentrations , mbds produce more subtle effects on 
16 mbds produce more subtle effects on microtubule dynamics , 
0 on microtubule dynamics , block critical cell signaling pathways 
0 microtubule dynamics , block critical cell signaling pathways , 
0 block critical cell signaling pathways , and prevent the 
18 signaling pathways , and prevent the microtubules from properly 
15 the microtubules from properly interacting with transient subcellular assemblies 
6 junctions ) whose subsequent stabilization and/or maturation are required 
2 whose subsequent stabilization and/or maturation are required for cell 
17 stabilization and/or maturation are required for cell motility and 
14 are required for cell motility and cell-cell interactions . 
0 for cell motility and cell-cell interactions . NULL NULL 
15 cell motility and cell-cell interactions . NULL NULL NULL 
16 whose actions more selectively target the tumor vasculature . 
0 more selectively target the tumor vasculature . NULL NULL 
0 NULL NULL NULL neurovascular effects of cd47 signaling : 
17 of cd47 signaling : promotion of cell death , 
5 : promotion of cell death , inflammation , and 
18 , inflammation , and suppression of angiogenesis in brain 
3 , and suppression of angiogenesis in brain endothelial cells 
0 unit emphasizes that common signals and substrates underlie the 
17 recent data suggest that activation of the integrin-associated protein 
15 that activation of the associated protein cd47 promotes neuronal 
0 activation of the integrin-associated protein cd47 promotes neuronal cell 
17 the integrin-associated protein cd47 promotes neuronal cell death . 
5 cd47 promotes neuronal cell death . NULL NULL NULL 
18 that cd47 may also negatively affect cerebral endothelial cells 
18 cd47 may also negatively affect cerebral endothelial cells ? 
19 cerebral endothelial cells ? exposure of wild-type primary mouse 
17 1 ( tsp-1 ) induced an increasing amount of 
0 tsp-1 ) induced an increasing amount of cell death 
5 increasing amount of cell death , whereas cytotoxicity was 
0 whereas cytotoxicity was significantly decreased in cerebral endothelial cells 
0 in cerebral endothelial cells derived from cd47 knockout mice 
17 NULL NULL the specific activating peptide , 4n1k , 
17 , 4n1k , similarly induced cell death in human 
5 , similarly induced cell death in human brain microvascular 
0 NULL NULL NULL NULL promotion of inflammation was also 
0 of inflammation was also involved because lower tsp-1 was 
17 tsp-1 was able to up-regulate the adhesion molecules intercellular 
0 able to up-regulate the adhesion molecules intercellular adhesion molecule-1 
0 the adhesion molecules intercellular adhesion molecule-1 and vascular cell 
0 molecule-1 and vascular cell adhesion molecule-1 . NULL NULL 
18 , cd47 signaling may suppress angiogenesis because 4n1k significantly 
3 cd47 signaling may suppress angiogenesis because 4n1k significantly inhibited 
18 angiogenesis because 4n1k significantly inhibited endothelial cell migration and 
14 significantly inhibited endothelial cell migration and tube formation in 
2 cell migration and tube formation in vitro . NULL 
18 that cd47 signaling can negatively affect the viability and 
18 cd47 signaling can negatively affect the viability and function 
0 affect the viability and function of cerebral endothelial cells 
0 endothelial cells , further supporting the notion that cd47 
0 cd47 may be a potential neurovascular target for stroke 
0 be a potential neurovascular target for stroke and brain 
18 NULL NULL NULL cisplatin reduces endothelial cell migration via 
14 cisplatin reduces endothelial cell migration via regulation of type 
16 endothelial cell migration via regulation of type 2-matrix metalloproteinase 
0 via regulation of type matrix metalloproteinase activity . NULL 
0 of type 2-matrix metalloproteinase activity . NULL NULL NULL 
16 study we investigated the effect of cisplatin on endothelial 
14 cisplatin on endothelial cell migration , an essential process 
17 cell migration , an essential process for vascular remodeling 
7 essential process for vascular remodeling and regeneration in several 
2 for vascular remodeling and regeneration in several physiological and 
19 ( huvec ) were treated with cisplatin and endothelial 
14 cisplatin and endothelial cell migration analyzed by fluorescence and 
0 by fluorescence and scratch-wound migration assay . NULL NULL 
0 NULL mmp2 and mmp9 activity were determined by zymographic 
17 assay , and mapk activation by western blotting analysis 
0 NULL NULL NULL NULL results : we demonstrated that 
0 provoked a time- and dependent decrease of huvec migration 
18 a time- and dose-dependent decrease of huvec migration ; 
14 dose-dependent decrease of huvec migration ; this effect was 
0 huvec migration ; this effect was clearly independent from 
0 this effect was clearly independent from its well known 
0 its well known cytotoxic activity . NULL NULL NULL 
0 NULL NULL NULL in addition , cisplatin markedly reduced 
18 addition , cisplatin markedly reduced mmp2 activity in both 
0 cisplatin markedly reduced mmp2 activity in both conditioned media 
17 and cell lysates , increased p38 mapk and jnk 
12 p38 mapk and jnk phosphorylation , but did not 
16 , but did not affect erk phosphorylation . NULL 
12 did not affect erk phosphorylation . NULL NULL NULL 
14 NULL NULL endothelial cell migration was attenuated by treatment 
18 endothelial cell migration was attenuated by treatment of cells 
19 migration was attenuated by treatment of cells with gm6001 
0 gm6001 , a non-specific inhibitor of mmps , or 
19 NULL NULL however , treatment of cells with sb202190 
16 respectively , did not affect huvec migration . NULL 
14 did not affect huvec migration . NULL NULL NULL 
0 NULL conclusion : these results suggested that cisplatin induced 
17 results suggested that cisplatin induced a reduction of endothelial 
18 that cisplatin induced a reduction of endothelial cell migration 
14 reduction of endothelial cell migration through an inhibition of 
18 cell migration through an inhibition of mmp2 activity by 
0 an inhibition of mmp2 activity by downstream signal transduction 
0 of mmp2 activity by downstream signal transduction pathways independent 
0 by downstream signal transduction pathways independent of jnk and 
16 downstream signal transduction pathways independent of jnk and p38 
17 jnk and p38 mapk activation . NULL NULL NULL 
16 NULL NULL NULL the modulation of platelet and endothelial 
15 platelet and endothelial cell adhesion to vascular graft materials 
16 NULL NULL NULL NULL controlled neo-endothelialisation is critical to 
0 NULL controlled neo-endothelialisation is critical to the patency of 
15 NULL endothelialisation and platelet adhesion to purified endothelial cell-derived 
0 and platelet adhesion to purified endothelial cell-derived perlecan , 
0 adhesion to purified endothelial derived perlecan , the major 
0 cell-derived perlecan , the major heparan sulfate ( hs 
17 NULL NULL NULL NULL enhanced endothelial cell growth and 
1 NULL enhanced endothelial cell growth and reduced platelet adhesion 
18 endothelial cell growth and reduced platelet adhesion were observed 
15 growth and reduced platelet adhesion were observed on the 
0 reduced platelet adhesion were observed on the perlecan coated 
0 when compared to uncoated controls implanted in the same 
19 compared to uncoated controls implanted in the same sheep 
17 was also found to stimulate endothelial cell proliferation in 
1 to stimulate endothelial cell proliferation in vitro over a 
14 6 days in the presence of plasma proteins and 
0 plasma proteins and fibroblastic growth factor 2 ( fgf-2 
1 of fgf-2 endothelial cell growth could not be maintained 
0 growth could not be maintained during this period . 
15 was found to be adhesive for platelets , however 
0 platelets , however after removal of the hs chains 
15 to perlecan , platelet adhesion and aggregation were supported 
15 , platelet adhesion and aggregation were supported . NULL 
0 adhesion and aggregation were supported . NULL NULL NULL 
0 NULL NULL NULL these results suggest a role for 
0 these results suggest a role for hs chains of 
17 graft patency by selectively promoting endothelial cell proliferation while 
1 selectively promoting endothelial cell proliferation while modulating platelet adhesion 
16 endothelial cell proliferation while modulating platelet adhesion . NULL 
15 proliferation while modulating platelet adhesion . NULL NULL NULL 
3 NULL NULL NULL tumour angiogenesis : its mechanism and 
0 tumour angiogenesis : its mechanism and therapeutic implications in 
0 and therapeutic implications in malignant gliomas . NULL NULL 
3 NULL NULL NULL NULL angiogenesis is a key event 
0 NULL angiogenesis is a key event in the progression 
2 key event in the progression of malignant gliomas . 
0 in the progression of malignant gliomas . NULL NULL 
0 NULL NULL NULL the presence of microvascular proliferation leads 
2 the presence of microvascular proliferation leads to the histological 
0 presence of microvascular proliferation leads to the histological diagnosis 
3 NULL NULL NULL tumour angiogenesis involves multiple cellular processes 
16 NULL NULL tumour angiogenesis involves multiple cellular processes including 
0 angiogenesis involves multiple cellular processes including endothelial cell proliferation 
1 processes including endothelial cell proliferation , migration , reorganisation 
14 endothelial cell proliferation , migration , reorganisation of extracellular 
0 , reorganisation of extracellular matrix and tube formation . 
2 extracellular matrix and tube formation . NULL NULL NULL 
0 NULL NULL NULL these processes are regulated by numerous 
0 NULL these processes are regulated by numerous pro-angiogenic and 
3 are regulated by numerous angiogenic and anti-angiogenic growth factors 
3 by numerous pro-angiogenic and angiogenic growth factors . NULL 
0 numerous pro-angiogenic and anti-angiogenic growth factors . NULL NULL 
3 NULL NULL NULL NULL angiogenesis inhibitors have been developed 
0 angiogenesis inhibitors have been developed to interrupt the angiogenic 
3 developed to interrupt the angiogenic process at the growth 
0 angiogenic process at the growth factor , receptor tyrosine 
0 kinase and intracellular kinase levels . NULL NULL NULL 
3 NULL NULL NULL other angiogenic therapies alter the immune 
18 NULL NULL other anti-angiogenic therapies alter the immune response 
0 NULL other anti-angiogenic therapies alter the immune response and 
0 therapies alter the immune response and endogeneous angiogenesis inhibitor 
3 immune response and endogeneous angiogenesis inhibitor levels . NULL 
0 response and endogeneous angiogenesis inhibitor levels . NULL NULL 
0 and endogeneous angiogenesis inhibitor levels . NULL NULL NULL 
3 NULL NULL NULL most angiogenic therapies for malignant gliomas 
18 NULL NULL most anti-angiogenic therapies for malignant gliomas are 
0 most anti-angiogenic therapies for malignant gliomas are in phase 
0 are in phase i/ii trials and only modest efficacies 
0 NULL NULL the greatest potential for angiogenesis inhibitors may 
3 the greatest potential for angiogenesis inhibitors may lie in 
0 may lie in their ability to combine safely with 
0 to combine safely with chemotherapy and radiotherapy . NULL 
0 safely with chemotherapy and radiotherapy . NULL NULL NULL 
16 NULL NULL NULL NULL regulation of thrombospondin-1 by natural 
17 studies show that progestins induce vascular endothelial growth factor 
0 progestins induce vascular endothelial growth factor ( vegf ) 
9 breast cancer cells that express mutant p53 protein . 
0 that express mutant p53 protein . NULL NULL NULL 
17 and synthetic progestins also induce thrombospondin-1 ( tsp-1 ) 
0 thrombospondin-1 ( tsp-1 ) mrna and protein in t47-d 
0 tsp-1 ) mrna and protein in t47-d and bt-474 
18 NULL NULL antiprogestin ru-486 inhibits the induction of vegf 
17 antiprogestin ru-486 inhibits the induction of vegf and tsp-1 
0 , suggesting that this effect of progestin is mediated 
16 effect of progestin is mediated by the progesterone receptor 
18 not puromycin , also blocks progestin-dependent induction of tsp-1 
17 puromycin , also blocks dependent induction of tsp-1 . 
17 , also blocks progestin-dependent induction of tsp-1 . NULL 
0 NULL NULL a putative response element was identified in 
16 progestin-pr complex might directly regulate transcription of the tsp-1 
10 complex might directly regulate transcription of the tsp-1 gene 
19 NULL conditioned medium from treated breast cancer cells stimulates 
17 progestin-treated breast cancer cells stimulates endothelial cell proliferation in 
1 cells stimulates endothelial cell proliferation in the absence though 
0 though not in the presence of antibody to tsp-1 
14 , indicating that tsp-1 secreted by breast cancer cells 
3 cancer cells could be angiogenic . NULL NULL NULL 
0 NULL NULL NULL since tumor cell-derived tsp-1 has the 
0 NULL NULL since tumor derived tsp-1 has the potential 
0 cell-derived tsp-1 has the potential to promote angiogenesis in 
17 has the potential to promote angiogenesis in the tumor 
3 the potential to promote angiogenesis in the tumor microenvironment 
0 promote angiogenesis in the tumor microenvironment , it could 
0 it could be a potential target for breast cancer 
0 could be a potential target for breast cancer therapy 
19 target for breast cancer therapy . NULL NULL NULL 
9 NULL NULL NULL c-ski overexpression promotes tumor growth and 
17 NULL NULL c-ski overexpression promotes tumor growth and angiogenesis 
0 NULL c-ski overexpression promotes tumor growth and angiogenesis through 
4 c-ski overexpression promotes tumor growth and angiogenesis through inhibition 
3 promotes tumor growth and angiogenesis through inhibition of transforming 
18 growth and angiogenesis through inhibition of transforming growth factor-beta 
0 through inhibition of transforming growth factor-beta signaling in diffuse-type 
0 product , is an important negative regulator of transforming 
0 , is an important negative regulator of transforming growth 
0 is an important negative regulator of transforming growth factor 
0 negative regulator of transforming growth factor ( tgf ) 
15 -beta family signaling through interaction with smad2 , smad3 
9 NULL NULL NULL high expression of c-ski has been 
0 NULL NULL we previously showed that disruption of tgf-beta 
18 we previously showed that disruption of tgf-beta signaling by 
0 of tgf-beta signaling by negative tgf-beta type ii receptor 
17 diffuse-type gastric carcinoma model accelerated tumor growth through induction 
0 gastric carcinoma model accelerated tumor growth through induction of 
4 carcinoma model accelerated tumor growth through induction of tumor 
17 accelerated tumor growth through induction of tumor angiogenesis by 
0 growth through induction of tumor angiogenesis by decreased expression 
3 through induction of tumor angiogenesis by decreased expression of 
18 of tumor angiogenesis by decreased expression of the anti-angiogenic 
9 tumor angiogenesis by decreased expression of the anti-angiogenic factor 
3 decreased expression of the angiogenic factor thrombospondin ( tsp 
0 , we examined the function of c-ski in human 
9 NULL NULL NULL NULL overexpression of c-ski inhibited tgf-beta 
18 NULL overexpression of c-ski inhibited tgf-beta signaling in ocum-2mln 
9 NULL interestingly , c-ski overexpression resulted in extensive acceleration 
0 interestingly , c-ski overexpression resulted in extensive acceleration of 
4 extensive acceleration of the growth of subcutaneous xenografts in 
9 NULL similar to tumors expressing dominant-negative tgf-beta type ii 
0 similar to tumors expressing negative tgf-beta type ii receptor 
17 revealed less fibrosis and increased angiogenesis in xenografted tumors 
3 less fibrosis and increased angiogenesis in xenografted tumors expressing 
9 angiogenesis in xenografted tumors expressing c-ski compared to control 
0 expressing c-ski compared to control tumors . NULL NULL 
17 NULL NULL NULL NULL induction of tsp-1 mrna by 
0 NULL induction of tsp-1 mrna by tgf-beta was attenuated 
18 mrna by tgf-beta was attenuated by c-ski in vitro 
10 in vitro , and expression of tsp-1 mrna was 
0 and expression of tsp-1 mrna was decreased in tumors 
18 of tsp-1 mrna was decreased in tumors expressing c-ski 
9 was decreased in tumors expressing c-ski in vivo . 
9 findings suggest that c-ski overexpression promotes the growth of 
17 suggest that c-ski overexpression promotes the growth of diffuse-type 
4 c-ski overexpression promotes the growth of diffuse-type gastric carcinoma 
17 diffuse-type gastric carcinoma through induction of angiogenesis . NULL 
3 carcinoma through induction of angiogenesis . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis novel therapeutic approach for 
3 NULL NULL NULL NULL angiogenesis is the biologic process 
2 the biologic process of forming new blood vessels . 
4 undoubtedly , blood vessels growth regulation is a vital 
16 , blood vessels growth regulation is a vital aspect 
3 under physiological conditions , angiogenesis is regulated by local 
16 conditions , angiogenesis is regulated by local balance between 
16 diseases state body loses control over angiogenesis . NULL 
3 body loses control over angiogenesis . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis diseases result when new 
3 NULL NULL NULL NULL dependent diseases result when new 
4 new blood vessels either grow excessively or insufficiently . 
3 NULL NULL NULL insufficient angiogenesis occurs in diseases such 
17 been clearly shown to stimulate angiogenesis in many experimental 
3 clearly shown to stimulate angiogenesis in many experimental models 
3 NULL NULL NULL therapeutic angiogenesis is the biological agents 
17 or bioactive material to stimulate the growth of new 
4 material to stimulate the growth of new blood vessels 
3 NULL NULL traditional coronary revascularization therapies such as coronary 
0 NULL traditional coronary revascularization therapies such as coronary angioplasty 
0 angioplasty or bypass graft surgery , act by restoring 
0 bypass graft surgery , act by restoring blood flow 
0 failure to normalize myocardial perfusion , due to the 
0 due to the concomitant presence or small of resistance 
3 in contrast , therapeutic angiogenesis is based on the 
2 concept that coronary collateral development may be stimulated by 
17 collateral development may be stimulated by pharmacological or molecular 
0 molecular means and can limit myocardial ischemia . NULL 
0 human and animal models support the notion that , 
3 notion that , various angiogenic growth factors and progenitor 
0 that , various angiogenic growth factors and progenitor cells 
17 and progenitor cells can enhance new blood vessels . 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
0 vegf ) , fibroblast growth factor ( fgf ) 
0 stem cells are currently used therapeutic stimulators for angiogenesis 
3 used therapeutic stimulators for angiogenesis . NULL NULL NULL 
0 artery disease is the major cause of death in 
0 the major cause of death in the developed societies 
0 of death in the developed societies and also an 
0 emerging health problem in developing countries like bangladesh therapeutic 
3 countries like bangladesh therapeutic angiogenesis may provide hope as 
0 hope as a new treatment modality for ischemic heart 
0 in place of current therapies . NULL NULL NULL 
0 NULL NULL NULL NULL use of uteroglobin for the 
0 of polyvalent , polyspecific fusion proteins . NULL NULL 
0 strategy to engineer and express stable and soluble human 
0 soluble human recombinant polyvalent/polyspecific fusion proteins . NULL NULL 
0 is based on the use of a central skeleton 
0 the use of a central skeleton of uteroglobin , 
0 and very soluble covalently linked homodimeric protein that is 
0 soluble covalently linked homodimeric protein that is very resistant 
3 ) specific for the angiogenesis marker domain b of 
18 an scfv able to neutralize tumor necrosis factor-alpha , 
0 scfv able to neutralize tumor necrosis factor-alpha , we 
0 able to neutralize tumor necrosis factor-alpha , we expressed 
0 necrosis factor-alpha , we expressed various biologically active uteroglobin 
0 we expressed various biologically active uteroglobin fusion proteins . 
0 various biologically active uteroglobin fusion proteins . NULL NULL 
0 NULL NULL NULL the results demonstrate the possibility to 
0 , compared with similar fusion proteins in which uteroglobin 
0 which uteroglobin was not used , the use of 
0 not used , the use of uteroglobin improved properties 
0 the use of uteroglobin improved properties of solubility and 
0 use of uteroglobin improved properties of solubility and stability 
0 the proteins without any aggregation or loss in protein 
0 without any aggregation or loss in protein and biological 
0 aggregation or loss in protein and biological activity . 
0 in protein and biological activity . NULL NULL NULL 
0 of cellular vascular endothelial growth factor ( vegf ) 
9 factor ( vegf ) expression in the course of 
0 NULL NULL NULL NULL introduction : increased angiogenesis in 
17 NULL NULL introduction : increased angiogenesis in bone marrow 
3 NULL introduction : increased angiogenesis in bone marrow is 
0 expresses a chimeric bcr/abl protein . NULL NULL NULL 
0 NULL NULL vascular endothelial growth factor ( vegf ) 
16 potent and a specific regulator of angiogenesis which principally 
3 a specific regulator of angiogenesis which principally targets endothelial 
0 of angiogenesis which principally targets endothelial cells and regulates 
16 targets endothelial cells and regulates several of their functions 
0 regulates several of their functions , including mitogenesis , 
0 mitogenesis , permeability and migration . NULL NULL NULL 
0 NULL NULL NULL the impact of elevated vegf expression 
17 NULL the impact of elevated vegf expression on the 
9 impact of elevated vegf expression on the course of 
9 the follow-up of vegf expression during the course of 
9 : we studied vegf expression of 85 cml patients 
0 , 25 in an accelerated phase ( ap ) 
9 NULL NULL the temporal expression ( percentage positivity per 
0 were studied using the immunohistochemical technique utilizing relevant monoclonal 
0 of blasts ) and clinical parameters ( organomegaly , 
0 bc ) of disease progression . NULL NULL NULL 
0 NULL NULL NULL NULL results : the expression ofvegf 
9 NULL results : the expression ofvegf protein was most 
0 : the expression ofvegf protein was most pronounced in 
9 the level of vegf expression correlated inversely with the 
9 NULL NULL NULL high expression of vegf correlated with 
0 with a shorter overall survival ( log rank , 
9 confirmed significance of the expression of vegf in dependence 
0 stage could be of clinical importance in deciding on 
0 deciding on the timing therapy . NULL NULL NULL 
0 data suggest that vegf plays a role in the 
0 that vegf plays a role in the biology of 
0 NULL NULL NULL NULL tumor angiogenesis : initiation and 
3 NULL NULL NULL tumor angiogenesis : initiation and targeting 
0 NULL tumor angiogenesis : initiation and targeting - therapeutic 
0 angiogenesis : initiation and targeting - therapeutic targeting of 
19 and targeting - therapeutic targeting of an fgf-binding protein 
0 therapeutic targeting of an binding protein , an angiogenic 
0 targeting of an fgf-binding protein , an angiogenic switch 
3 fgf-binding protein , an angiogenic switch molecule , and 
0 NULL NULL NULL NULL tumor angiogenesis has been related 
3 NULL NULL NULL tumor angiogenesis has been related to 
17 been related to the initiation as well as progression 
17 initiation as well as progression toward more aggressive behavior 
0 in particular , the activity of angiogenic factors is 
3 , the activity of angiogenic factors is crucial for 
0 of angiogenic factors is crucial for tumor progression . 
0 factors is crucial for tumor progression . NULL NULL 
2 is crucial for tumor progression . NULL NULL NULL 
14 we previously characterized a secreted fibroblast growth factor-binding protein 
0 characterized a secreted fibroblast growth factor-binding protein ( fgf-bp 
0 a secreted fibroblast growth binding protein ( fgf-bp ) 
0 secreted fibroblast growth factor-binding protein ( fgf-bp ) as 
0 chaperone molecule , which binds to various fgfs , 
0 to various fgfs , enhances fgf-mediated biochemical and biologic 
0 various fgfs , enhances mediated biochemical and biologic events 
17 and importantly is a crucial rate-limiting factor for tumor-dependent 
0 importantly is a crucial limiting factor for tumor-dependent angiogenesis 
17 crucial rate-limiting factor for dependent angiogenesis . NULL NULL 
3 rate-limiting factor for tumor-dependent angiogenesis . NULL NULL NULL 
0 generated monoclonal antibodies that target fgf-bp protein and used 
0 antibodies that target fgf-bp protein and used them as 
0 target fgf-bp protein and used them as a tool 
9 and pattern of fgf-bp expression during the malignant progression 
0 fgf-bp expression during the malignant progression of pancreas and 
2 expression during the malignant progression of pancreas and colorectal 
17 that fgf-bp is dramatically upregulated during the initiation of 
2 dramatically upregulated during the initiation of colorectal and pancreatic 
0 NULL NULL NULL NULL crucial genetic events underlying the 
2 genetic events underlying the initiation and progression of colorectal 
2 underlying the initiation and progression of colorectal and pancreatic 
16 particular focus on the modulation of angiogenesis and antiangiogenic 
3 on the modulation of angiogenesis and antiangiogenic therapies are 
3 modulation of angiogenesis and angiogenic therapies are discussed . 
19 of angiogenesis and antiangiogenic therapies are discussed . NULL 
17 we propose that the upregulation of the secreted fgf-bp 
14 the upregulation of the secreted fgf-bp protein during early 
0 of the secreted fgf-bp protein during early phases of 
0 cancer could make this protein a possible serum marker 
0 serum marker indicating the presence of high-risk premalignant lesions 
0 furthermore , the biological activity of fgf-bp is neutralized 
0 monoclonal antibodies suggesting the potential for antibody-based therapeutic targeting 
0 potential for antibody-based therapeutic targeting . NULL NULL NULL 
0 NULL NULL experimental drug therapy of peritumoral brain edema 
0 NULL four drugs with potential anti-peritumoral brain edema activity 
18 potential anti-peritumoral brain edema activity were studied using the 
0 the vx2 rabbit brain tumor model . NULL NULL 
18 recent reports of anti-edema activity in non steroidal anti-inflammatory 
0 of glucocorticoid and mineralocorticoid effects and their structural similarity 
0 mineralocorticoid effects and their structural similarity to glucocorticoids . 
0 NULL NULL NULL the protein and water component of 
0 the test drugs demonstrated significant anti-edema activity . NULL 
18 drugs demonstrated significant anti-edema activity . NULL NULL NULL 
18 nsaid 's have anti-edema activity and suggests that there 
18 'angiostatic ' and anti-edema activity in certain steroid compounds 
0 NULL NULL NULL low-level radiation effects on functional vascular 
16 NULL NULL low-level x-radiation effects on functional vascular changes 
16 effects on functional vascular changes in syrian hamster cheek 
0 pouch epithelium during hydrocarbon carcinogenesis . NULL NULL NULL 
16 NULL NULL NULL NULL effects of repeated low-level x 
0 of repeated low-level x radiation on functional microvascular changes 
16 radiation on functional microvascular changes in hamster cheek pouch 
0 epithelium during and following carcinogenesis by 7 , 12-dimethylbenz 
0 NULL NULL prior studies showed enhancement of such carcinogenesis 
0 NULL prior studies showed enhancement of such carcinogenesis by 
0 showed enhancement of such carcinogenesis by repeated 20 rad 
19 rad head and neck radiation exposures , and it 
0 proposed that one possible mechanism was radiogenic alteration of 
0 manner which favored subsequent tumor development . NULL NULL 
2 which favored subsequent tumor development . NULL NULL NULL 
19 NULL NULL hamsters were treated with either radiation , 
0 were treated with either radiation , dmba , radiation 
0 radiation , dmba , radiation + dmba , or 
19 dmba , or no treatment . NULL NULL NULL 
0 NULL NULL animals were sacrificed at 3-week intervals from 
0 to 39 weeks after treatments began . NULL NULL 
0 vascular volume and permeability changes were studied by fractional 
0 the vascular parameters , treatment types , elapsed time 
0 , elapsed time , presence of the carcinogen , 
0 carcinogen , and histopathologic changes . NULL NULL NULL 
0 NULL NULL NULL all treatments resulted in significant changes 
0 NULL NULL all treatments resulted in significant changes in 
0 all treatments resulted in significant changes in vascular volume 
16 treatments resulted in significant changes in vascular volume with 
0 , while only dmba treatments alone resulted in significant 
0 only dmba treatments alone resulted in significant changes in 
0 treatments alone resulted in significant changes in vascular permeability 
16 alone resulted in significant changes in vascular permeability with 
16 frank neoplasms , volumetric changes in dmba only and 
0 in dmba only and radiation only groups were similar 
16 similar , while volume changes in dmba + radiation 
0 changes in dmba + radiation groups increased slowly to 
17 dmba + radiation groups increased slowly to a peak 
0 other groups and then declined steadily to levels similar 
0 then declined steadily to levels similar to the radiation 
0 levels similar to the radiation only group . NULL 
0 studies , there were significant vascular volume differences between 
0 dmba and dmba + radiation groups of tumor-bearing cheek 
0 those of dmba + radiation . NULL NULL NULL 
0 NULL NULL NULL NULL radiation significantly affected dmba-associated vascular 
16 NULL NULL radiation significantly affected dmba-associated vascular volume and 
16 NULL radiation significantly affected associated vascular volume and permeability 
0 vascular volume and permeability changes during carcinogenesis . NULL 
0 and permeability changes during carcinogenesis . NULL NULL NULL 
0 the relationship of these changes to the enhancement of 
17 these changes to the enhancement of dmba carcinogenesis include 
0 the enhancement of dmba carcinogenesis include : radiation blocking 
0 dmba carcinogenesis include : radiation blocking normal capillary proliferative 
0 carcinogenesis include : radiation blocking normal capillary proliferative and/or 
4 radiation blocking normal capillary proliferative and/or dilatory responses to 
0 inflammation secondary to neoplastic changes ; radiation-induced focal increases 
0 to neoplastic changes ; radiation focal increases in the 
0 to neoplastic changes ; induced focal increases in the 
0 changes ; radiation-induced focal increases in the pericapillary connective 
17 tissue histohematic barrier , stimulating angiogenesis but reducing nutrient 
3 histohematic barrier , stimulating angiogenesis but reducing nutrient diffusion 
0 , stimulating angiogenesis but reducing nutrient diffusion ; radiation 
0 reducing nutrient diffusion ; radiation exposures sensitizing vascular endothelium 
3 vascular endothelium to subsequent angiogenic stimulation from premalignant tissues 
17 endothelium to subsequent angiogenic stimulation from premalignant tissues ; 
0 dmba vascular and epithelial effects partially or completely blocking 
18 effects partially or completely blocking radiation effects on epithelial 
0 partially or completely blocking radiation effects on epithelial and/or 
16 or completely blocking radiation effects on epithelial and/or endothelial 
0 endothelial cells ; and radiation damage to vessel walls 
6 cells ; and radiation damage to vessel walls partially 
0 walls partially or fully inhibiting normal physiologic mechanisms of 
6 mechanisms of repairing dmba damage to the vessels . 
0 of vascular casts was used to investigate three experimental 
3 three experimental models of neovascularization . NULL NULL NULL 
2 representation of the newly formed blood vessels and permitted 
4 vessels within normal and proliferating vascular networks . NULL 
4 enabled the evolution of proliferating vessels into arterioles and 
17 NULL mast cell heparin stimulates migration of capillary endothelial 
14 mast cell heparin stimulates migration of capillary endothelial cells 
14 NULL NULL NULL NULL migration of capillary endothelial cells 
0 endothelial cells is an important component of angiogenesis in 
3 an important component of angiogenesis in vivo . NULL 
17 NULL NULL NULL NULL increased numbers of mast cells 
16 mast cells have been associated with several types of 
3 with several types of angiogenesis . NULL NULL NULL 
0 NULL NULL we have used a quantitative assay in 
0 demonstrate that mast cells release a factor that significantly 
17 a factor that significantly increases bovine capillary endothelial cell 
14 bovine capillary endothelial cell migration . NULL NULL NULL 
0 NULL the factor is present in medium conditioned by 
17 NULL NULL NULL the stimulatory effect of mast cells 
17 NULL NULL the stimulatory effect of mast cells on 
14 of mast cells on migration is specific for capillary 
16 cells have no mitogenic activity for capillary endothelial cells 
17 tested , only heparin stimulated capillary endothelial cell migration 
14 stimulated capillary endothelial cell migration in vitro . NULL 
17 a variety of sources stimulated capillary endothelial cell migration 
14 stimulated capillary endothelial cell migration to the same degree 
17 degree but did not stimulate migration of several other 
14 but did not stimulate migration of several other cell 
0 NULL NULL NULL the migration activity of heparin and 
0 NULL NULL the migration activity of heparin and mast 
18 cell conditioned medium was blocked by specific antagonists of 
0 NULL NULL NULL the migration activity of mast cell 
0 NULL NULL the migration activity of mast cell conditioned 
0 NULL NULL NULL these results suggest that the role 
16 results suggest that the role of mast cells in 
3 of mast cells in angiogenesis may be to enhance 
17 angiogenesis may be to enhance migration of the endothelial 
14 may be to enhance migration of the endothelial cells 
4 the endothelial cells of growing capillaries . NULL NULL 
3 heparin-steroid conjugates : new angiogenesis inhibitors with antitumor activity 
18 angiogenesis inhibitors with antitumor activity in mice . NULL 
3 NULL NULL inhibitors of angiogenesis hold potential in the 
0 inhibitors of angiogenesis hold potential in the treatment of 
19 hold potential in the treatment of cancer and other 
0 where the disease is caused or maintained by the 
0 disease is caused or maintained by the inappropriate growth 
4 maintained by the inappropriate growth of blood vessels . 
0 NULL NULL in the present study , a novel 
0 study , a novel inhibitor of angiogenesis was synthesized 
3 a novel inhibitor of angiogenesis was synthesized by covalently 
0 inhibitor of angiogenesis was synthesized by covalently linking a 
3 acid-labile bond to the angiogenic steroid , cortisol . 
15 heparin derivative , which binds to sulfated polyanion receptors 
0 intracellular compartments should then lead to release of the 
14 should then lead to release of the cortisol and 
0 of the cortisol and expression of its antiproliferative activity 
0 expression of its antiproliferative activity . NULL NULL NULL 
0 the stability of hah-cortisol showed that it was stable 
19 NULL NULL NULL NULL treatment of murine pulmonary capillary 
0 respect to cortisol ) suppressed their dna synthesis by 
0 ) suppressed their dna synthesis by 50 % and 
18 by 50 % and inhibited their migration into wounded 
14 % and inhibited their migration into wounded areas of 
0 cortisol ) did not suppress the dna synthesis of 
0 not suppress the dna synthesis of lewis lung carcinoma 
3 NULL sponge implants retarded vascularization of the sponge , 
18 directly into the sponge abolished vascularization for as long 
3 into the sponge abolished vascularization for as long as 
4 apparent toxicity retarded the growth of solid s.c . 
19 these assays , equivalent treatments with a mixture of 
0 cortisol was significantly less effective . NULL NULL NULL 
18 NULL NULL the antiproliferative effect of hah-cortisol on endothelial 
0 on endothelial cells appeared independent of the glucocorticoid activity 
0 independent of the glucocorticoid activity of the steroid since 
0 lacking glucocorticoid or mineralocorticoid activity , was even more 
0 , was even more effective at inhibiting dna synthesis 
0 even more effective at inhibiting dna synthesis by murine 
0 effective at inhibiting dna synthesis by murine pulmonary capillary 
3 a new class of angiogenesis inhibitors for the treatment 
19 angiogenesis inhibitors for the treatment of cancer and other 
3 of cancer and other angiogenic diseases . NULL NULL 
19 NULL NULL NULL [ treatment of the diabetic foot 
0 result is hypoxia which impairs wound healing . NULL 
0 NULL NULL NULL it leads to enhanced oxygenation of 
0 NULL it leads to enhanced oxygenation of the affected 
16 enhanced oxygenation of the affected tissues , has an 
0 , has an antiseptic effect , reduces edema , 
18 an antiseptic effect , reduces edema , and accelerates 
9 , and accelerates collagen production and angiogenesis , thus 
3 accelerates collagen production and angiogenesis , thus enhancing tissue 
17 and angiogenesis , thus enhancing tissue repair . NULL 
2 , thus enhancing tissue repair . NULL NULL NULL 
0 wounds which did not respond to treatment for at 
0 did not respond to treatment for at least 3 
0 least 3 months were treated by hbo . NULL 
0 measurements of tissue po2 showed elevation from 20 +/- 
0 of tissue po2 showed elevation from 20 +/- 10 
0 NULL NULL they were treated with hbo in 56 
0 1 there was partial response , in 1 minimal 
0 , in 1 minimal response , and in 1 
0 in 1 a transient response . NULL NULL NULL 
0 a safe mode of therapy , but further studies 
0 but further studies are required to establish its efficacy 
0 required to establish its efficacy and to ascertain which 
0 immune system is to protect cells from invasion by 
0 to protect cells from invasion by microorganisms . NULL 
0 body has three equally important interactive immune defense systems 
0 equally important interactive immune defense systems , all of 
0 of which are profoundly disrupted with major burn injury 
0 are profoundly disrupted with major burn injury . NULL 
0 NULL NULL the immune response to burn injury is 
0 injury is immediate , prolonged , and severe . 
0 end result in individuals surviving burn shock is immunosuppression 
0 is immunosuppression , with increased susceptibility to potentially fatal 
0 NULL nursing actions to support the humoral and cell-mediated 
0 support the humoral and mediated immune system of the 
0 patient include providing nutritional support to maintain serum protein 
0 support to maintain serum protein levels at optimal levels 
0 to maintain serum protein levels at optimal levels ; 
0 protein levels at optimal levels ; measures to decrease 
18 levels ; measures to decrease edema and promote angiogenesis 
17 to decrease edema and promote angiogenesis in areas of 
3 decrease edema and promote angiogenesis in areas of partial-thickness 
0 partial-thickness injury ; meticulous treatment of the wound to 
0 of the wound to prevent infection and promote healing 
0 the wound to prevent infection and promote healing ; 
0 to prevent infection and promote healing ; monitoring of 
0 ; monitoring of antibiotic use ; conservative use of 
0 antibiotic use ; conservative use of invasive techniques , 
0 vascular access devices ; maintenance of fluid and electrolyte 
3 NULL NULL NULL autocrine angiogenic vascular prosthesis with bone 
19 prosthesis with bone marrow transplantation . NULL NULL NULL 
3 a vascular prosthesis needs angiogenesis for endothelialization of the 
0 natural and permanent antithrombogenic properties . NULL NULL NULL 
17 NULL NULL NULL to induce capillary growth into the 
4 NULL to induce capillary growth into the graft , 
0 the graft , we developed a method of transplanting 
0 , strong enough to survive , and create blood 
17 create blood cells , resulting in the inducement of 
4 the inducement of capillary growth . NULL NULL NULL 
19 NULL the grafts were implanted in the abdominal aortic 
5 NULL NULL marrow cells survived and continued exogenous hemopoiesis 
0 reactive to basic fibroblast growth factor ( bfgf ) 
0 had complete endothelialization and maintained their patency . NULL 
0 without bone marrow were implanted as controls . NULL 
0 marrow were implanted as controls . NULL NULL NULL 
0 NULL NULL endothelialization was present at anastomotic sites , 
0 four out of seven control grafts were patent with 
0 with its unique native properties produced autocrine angiogenicity in 
0 its unique native properties produced autocrine angiogenicity in the 
3 native properties produced autocrine angiogenic in the graft . 
16 NULL NULL NULL the effects of radiation on neovascularization 
0 NULL the effects of radiation on neovascularization in a 
3 effects of radiation on neovascularization in a rat model 
0 it is thought that radiation treatment inhibits neovascularization of 
0 is thought that radiation treatment inhibits neovascularization of recipient 
18 thought that radiation treatment inhibits neovascularization of recipient and/or 
3 that radiation treatment inhibits neovascularization of recipient and/or graft 
0 abnormalities in wound healing associated with radiation therapy . 
0 wound healing associated with radiation therapy . NULL NULL 
0 healing associated with radiation therapy . NULL NULL NULL 
3 model that measures the neovascularization of an implanted foreign 
0 the neovascularization of an implanted foreign material . NULL 
19 ptfe ) sheets were implanted adjacent to both superficial 
0 daily fractions of electron-beam radiation ( 300 cgy each 
0 cgy each ) were delivered to the implant in 
0 as a nonirradiated internal control . NULL NULL NULL 
0 NULL NULL unirradiated animals showed equal neovascularization of both 
3 unirradiated animals showed equal neovascularization of both implants . 
19 NULL rats that were irradiated twice ( single fractions 
0 and 24 hours after implantation ) did not show 
0 did not show a significant decrease in the neovascularization 
18 not show a significant decrease in the neovascularization of 
3 significant decrease in the neovascularization of the irradiated implant 
0 the neovascularization of the irradiated implant compared with the 
0 compared with the contralateral control implant . NULL NULL 
0 the implants that were irradiated three times ( single 
0 and 48 hours after implantation ) demonstrated significantly diminished 
18 implantation ) demonstrated significantly diminished ( greater than 25 
3 less than 0.05 ) neovascularization beyond day 7 , 
0 7 , whereas implants irradiated only at 48 hours 
0 at 48 hours after implantation did not . NULL 
3 NULL NULL interestingly , neovascularization of the implants irradiated 
0 neovascularization of the implants irradiated with 10 fractions ( 
18 ) was not significantly decreased compared with irradiation with 
0 NULL NULL NULL irradiation delivered before implantation ( 900 
0 NULL irradiation delivered before implantation ( 900 cgy ) 
18 ( 900 cgy ) inhibited neovascularization significantly less than 
3 900 cgy ) inhibited neovascularization significantly less than the 
0 than the same dose administered after implantation . NULL 
0 same dose administered after implantation . NULL NULL NULL 
0 NULL NULL NULL the results of this study suggest 
18 is the threshold for impaired tissue revascularization provided that 
3 threshold for impaired tissue revascularization provided that treatment is 
0 tissue revascularization provided that treatment is delivered immediately after 
0 provided that treatment is delivered immediately after implantation over 
0 is delivered immediately after implantation over a 48-hour interval 
3 NULL prognostic value of angiogenesis in operable non-small cell 
3 NULL NULL NULL tumour angiogenesis is an important factor 
0 tumour angiogenesis is an important factor for tumour growth 
4 important factor for tumour growth and metastasis . NULL 
14 for tumour growth and metastasis . NULL NULL NULL 
0 disease outcome , the results were not conclusive and 
0 NULL NULL in the present study , the vascular 
0 NULL there was a significant correlation between eye appraisal 
0 histology , grade , proliferation index ( ki67 ) 
9 or egfr or p53 expression . NULL NULL NULL 
3 a higher grade of angiogenesis ( p = 0.05 
0 related to lymph node metastasis ( p less than 
0 a univariate analysis of survival showed that vascular grade 
0 univariate analysis of survival showed that vascular grade was 
0 grade was the most significant prognostic factor ( p 
0 not found to be independent prognostic factors , since 
0 grade was the only independent prognostic factor ( p 
0 NULL NULL NULL kaplan-meier survival curves showed a statistically 
0 NULL kaplan-meier survival curves showed a statistically significant worse 
0 curves showed a statistically significant worse prognosis for patients 
0 but no difference was observed between low and medium 
3 these data suggest that angiogenesis in operable non-small cell 
0 lung cancer is a major prognostic factor for survival 
0 major prognostic factor for survival and , among the 
14 related to cancer cell migration to lymph nodes . 
0 of vascular grading in clinical trials on adjuvant chemotherapy 
0 vascular grading in clinical trials on adjuvant chemotherapy and/or 
19 clinical trials on adjuvant chemotherapy and/or radiotherapy could substantially 
19 on adjuvant chemotherapy and/or radiotherapy could substantially contribute in 
0 and/or radiotherapy could substantially contribute in defining groups of 
0 might benefit from cytotoxic treatment . NULL NULL NULL 
0 alphavbeta3 requirement for sustained activated protein kinase activity during 
0 requirement for sustained mitogen-activated protein kinase activity during angiogenesis 
0 sustained mitogen-activated protein kinase activity during angiogenesis . NULL 
3 protein kinase activity during angiogenesis . NULL NULL NULL 
3 NULL NULL NULL NULL angiogenesis depends on growth factors 
17 NULL NULL NULL angiogenesis depends on growth factors and 
0 NULL angiogenesis depends on growth factors and vascular cell 
15 factors and vascular cell adhesion events . NULL NULL 
0 NULL NULL integrins and growth factors are capable of 
17 factors are capable of activating the ras/map kinase pathway 
0 , yet how these signals influence endothelial cells during 
16 yet how these signals influence endothelial cells during angiogenesis 
3 influence endothelial cells during angiogenesis is unknown . NULL 
17 NULL NULL NULL upon initiation of angiogenesis with basic 
3 NULL upon initiation of angiogenesis with basic fibroblast growth 
0 angiogenesis with basic fibroblast growth factor ( bfgf ) 
0 ) , endothelial cell activated protein ( map ) 
0 , endothelial cell mitogen-activated protein ( map ) kinase 
0 kinase ( erk ) activity was detected as early 
0 erk ) activity was detected as early as 5 
0 initial wave of erk activity ( 5-120 min ) 
0 , whereas the sustained activity ( 4-20 h ) 
18 NULL NULL NULL NULL inhibition of map kinase kinase 
17 ) during this sustained dependent erk signal blocked the 
18 sustained alphavbeta3-dependent erk signal blocked the formation of new 
2 erk signal blocked the formation of new blood vessels 
16 blood vessels while not influencing preexisting blood vessels on 
18 NULL NULL NULL NULL inhibition of mek also blocked 
0 inhibition of mek also blocked growth factor induced migration 
0 of mek also blocked growth factor induced migration but 
17 also blocked growth factor induced migration but not adhesion 
14 blocked growth factor induced migration but not adhesion of 
15 induced migration but not adhesion of endothelial cells in 
3 NULL NULL therefore , angiogenesis depends on sustained erk 
17 NULL therefore , angiogenesis depends on sustained erk activity 
0 depends on sustained erk activity regulated by the ligation 
16 on sustained erk activity regulated by the ligation state 
0 activity regulated by the ligation state of both a 
0 state of both a growth factor receptor and integrin 
0 NULL NULL basic fibroblast growth factor : a missing 
17 between collagen vii , increased collagenase , and squamous 
17 type vii and have elevated levels of fibroblast collagenase 
0 vii and have elevated levels of fibroblast collagenase , 
0 , and a greatly increased risk of cutaneous squamous 
17 disorders do not have elevated collagenase or an increased 
0 elevated collagenase or an increased risk of squamous cell 
0 NULL NULL NULL the connection between collagen type vii 
0 between collagen type vii deficiency , increased collagenase , 
17 type vii deficiency , increased collagenase , and squamous 
0 , as well as unaffected family members of rdeb 
14 was tested for the presence of basic fibroblast growth 
0 presence of basic fibroblast growth factor ( bfgf ) 
0 bfgf ) using a sensitive radioimmunoassay . NULL NULL 
0 NULL NULL NULL NULL results : fifty-one percent of 
17 patients with rdeb had elevated levels ( greater than 
0 with rdeb had elevated levels ( greater than 5000 
17 patients with jeb had elevated levels of bfgf . 
0 with jeb had elevated levels of bfgf . NULL 
0 twenty-one percent of clinically unaffected family members had elevated 
17 unaffected family members had elevated levels of bfgf , 
0 family members had elevated levels of bfgf , and 
17 patients with ebs had elevated levels of bfgf . 
0 with ebs had elevated levels of bfgf . NULL 
17 NULL the frequency of elevated bfgf values among all 
0 all groups was statistically significant ( p = 0.002 
0 ) , and the levels of bfgf in rdeb 
17 rdeb patients were significantly elevated compared with those of 
17 patients with rdeb have elevated levels of bfgf , 
0 with rdeb have elevated levels of bfgf , which 
0 bfgf , which may contribute to increased fibroblast collagenase 
17 which may contribute to increased fibroblast collagenase and the 
2 fibroblast collagenase and the development of squamous cell carcinoma 
0 NULL NULL NULL these results suggest a novel treatment 
0 results suggest a novel treatment for rdeb , namely 
3 rdeb , namely , angiogenesis inhibitors , which may 
18 inhibitors , which may antagonize the effects of bfgf 
18 which may antagonize the effects of bfgf in this 
0 no other means of treatment for this disorder , 
0 pad serving as a control . NULL NULL NULL 
0 supply of both the control and the experimental fat 
0 experimental fat pads was isolated and ligated , and 
0 perfused with fluorescein or lead oxide ; and examined 
0 NULL NULL NULL NULL significant differences were found between 
0 were found between the control and experimental fat pads 
0 fully with fluorescein and lead oxide ; control fat 
0 and lead oxide ; control fat pads were found 
0 NULL NULL NULL the lead oxide group revealed extensive 
4 oxide group revealed extensive growth of blood vessels from 
0 were visualized in the controls . NULL NULL NULL 
0 , sections of the control and experimental flaps were 
3 , with evidence of neovascularization , was found in 
0 fat that characterized the controls . NULL NULL NULL 
0 and may have extensive application in various areas of 
0 various areas of plastic surgery . NULL NULL NULL 
